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lyl, l-phenyltetrazolyl, 2-thioxo-3-thiazolidinyl-, pyri

lected from the group consisting of nitro, and penta
fluoro; benzyl, CHZCFZCFZCF 3, l-lower alkyl tetrazo

dyl and benzothiazolyl, provided that when R is parani
trophenyl, R’ is other than tertiary-butyl, benzyl or
cyclohexyl, and when X is sulfur, R is other than ben

zyl.
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Elastase Induced Experimental Emphysema by Oral
PEPTIDE ELASTASE INHIBITORS AND
METHODS

Administration of a Synthetic Elastase Inhibitor,”, A.

Janoff and R. Dearing, Am. J. Respir. Dis., 121, 1025-3
(1980), there 'is considerable question whether such
reactive agents could be used for treating emphysema in
humans. This is not surprising since the alkylating moi

FIELD OF THE INVENTION

This invention relates to inhibitors of the enzyme

eties in these inhibitors might render them toxic when

elastase and more particularly relates to the use of cer

tain novel peptides containing the carbamate functional

used on a continuous basis. To be suitable for human

ity which are active-site directed inhibitors of the en
zyme elastase.

use, an~ enzyme inhibitor has to show a high degree of
selectively and must have minimal toxic side effects. As
a result, most drugs are molecules that reversibly bind
to speci?c enzymes or receptor sites. Examples are the

BACKGROUND OF THE INVENTION

Proteinases from polymorphonuclear leukocytes and

elastase and cathepsin G), appear to be responsible for

carbamate esters physostigmine and neostigmine which
have been clinically used as inhibitors of acetyl choline
esterases, A. G. Gilman, L. S. Goodman, and A.

the chronic tissue destruction associated with inflamma
tion, arthritis and emphysema. During infection or in

Gilman, “The pharmacological Basis of Therapeutics”,
p. 101, MacMillan Publishing Co. (1980).

macrophages, especially elastases (human leukocyte

?ammation, the normal lung is protected from proteo

There accordingly remains a need in the art for com

lytic digestion by the protease inhibitor, ai-antitrypsin.

pounds which are speci?c and active-site directed inhib

The protective mechanism appears to be nonoperative 20 itors of the enzyme elastase which are not subject to the
in individuals with an ai-antitrypsin de?ciency due to
disadvantages of compounds known in the art for this
genetic or other causes. Synthetic elastase inhibitors
purpose.

capable of replacing al-antitrypsin therefore appear to
be useful in the treatment of pulmonary emphysema and

SUMMARY OF THE INVENTION

25
related diseases.
It is accordingly one object of the present invention
Several types of elastase inhibitors have been re
to provide novel compounds which are inhibitors of the

ported in the literature. These include peptide chloro

enzyme elastase.

methyl ketones as described in “Inhibition of Human

A further object of the invention is to provide spe

Leukocyte Elastase by Peptide Chloromethyl Ke

ci?c active-site directed inhibitors of the enzyme elas
tones”, P. M. Tuhy and J. C. Powers, FEBS Letters, 50, 30 tase which are substituted carbamates.

359-61 (1975); “Speci?city of Porcine Pancreatic Elas
tase, Human Leukocyte Elastase and Cathepsin G. Inhi
bition with Peptide Chloromethyl Ketones”, J. C. Pow

A still further object of the invention is to provide

methods for the speci?c inhibition of porcine pancreatic
elastase and human leukocyte elastase by substituted

ers, B. F. Gupton, A. D. Harley, N. Nishino and R. J.

Whitley, Biochem. Biophys. Acto. 485, 156-66 (1977);

35

carbamate compounds without affecting the similar
serine dependent proteases, bovine pancreatic trypsin
and chymotrypsin.

azapeptides “Proteinase Inhibitors. 1. Inhibitors of Elas
tase”, C. P. Dorn, M. Zimmerman, S. S. Yang, E. C.
An even further object of the invention is to provide
Yurewicz, B. M. Ashe, R. Frankshun and H. Jones, J.
pharmaceutical compositions useful in the speci?c inhi
Med. Chem, 20, 1464-68 (1977); “Reaction of Serine
Proteases with Aza-amino Acid and Ala-peptide De 40 bition of porcine pancreatic elastase, said compositions
containing as the active and effective component, cer
rivatives”, J. C. Powers and B. F. Guptcn, Meth. En
tain substituted and novel carbamate compounds.
zymol, 46, 208-16 (1977); sulfonyl ?uorides “Speci?city

and Reactivity of Human Leukocyte Elastase, Porcine
Pancreatic Elastase, Human Granulocyte Cathepsin G,
and Bovine Pancreatic Elastase, Human Granulocyte
Cathepsin G, and Bovine Pancreatic Chymotrypsin

Further objects and advantages of the present inven

tion will become apparent as the description thereof
45 proceeds.

~

In satisfaction of the foregoing objects and advan
tages, the present invention provides substituted carb
mate compounds of the following formula:

with Arylsulfonyl Fluorides. Discovery of a new series

of potent and speci?c irreversible Elastase Inhibitors”,
T. Yoshimura, L. N. Barker and J. C. Powers, J. Biol.

Chem., 257, 5077-84 (1982); heterocyclic acrylating

50

II
agents-”Inhibition of Elastase and Other Serine Pro
teases by Heterocyclic Acylating Agents”, M. Zimmer
R.
man, I-I. Morman, D. Mulvey, H. Jones, R. Frankshun
and B. M. Ashe, J. Biol. Chem, 255, 9848-51 (1980);
“Selective Inhibition of Human Leukocyte Elastase and 55 wherein Z is selected from the group consisting of
R"O—Suc—where R” is lower alkyl of 1 to 3 carbon
Bovine oil-Chymotrypsin by Novel Heterocycles”, B.
atoms, and CF3CO—; X is oxygen or sulfur, R’ is se
M. Ashe, R. L. Clark, H. Jones and M. Zimmerman, J.
lected from the group consisting of straight or second
Biol. Chem, 256: 11603-6 (1981); imidazole N-carboxa
ary branch-chained alkenyl of 2 to 4 carbon, atoms,
mides, W. C. Groutas, R. C. Badger, T. D. Ocain, D.
Felker, J. Frankson and M. Theodorakis, Biochem. Bio 60 alkynyl of 2 to 4 carbon atoms, alkyl of l to 4 carbon
atoms, cycloalkyl of 3 to 6 carbon atoms, preferably
phys. Res. Commun., 95, 1890 (1980); and p-nitrophenyl
cyclopropyl or cyclohexyl, and benzyl, and R is se
N alkyl carbamates, “p-Nitrophenyl Carbamates as

Z--Ala-Ala—-Pro-CIh-Iil-C-X-R

Active-Site-Speci?c Reagents for Serine Proteases”, R.
E. Sco?eld, R. P. Werner and F. Wold, Biochemistry,

lected from the group consisting of substituted or un

substituted phenyl wherein the substituents are selected

Although some peptide chloromethyl ketones have

from the group consisting of nitro, preferably p-nitro,
and fluoro, preferably pentafluoro; benzyl,

been shown to be effective in preventing elastase in
duced emphysema in animal models “Prevention of

lyl-, 2-thioxo-3-thiazolindinyl-, pyridyl, and benzo

16, 2492 (1977).

'

65

CH2CF2CF2CF3, l-lower alkyl- and l-phenyl tetrazo

3

4,643,991

4

thiazolyl, provided that when R is para-nitrophenyl, R’
is other than tertiary-butyl, benzyl, or cyclohexyl, and

cycloalkyl of 3 to 6 carbon atoms, preferably cyclopro
pyl or cyclohexyl, and benzyl, and R is selected from

when X is sulfur, R is other than benzyl.

the group consisting of substituted or unsubstituted
phenyl wherein the substituents are selected from the

The invention also provides elastase inhibiting phar
maceutical compositions containing these novel substi

group consisting of nitro, preferably p-nitro, and ?uoro,
preferably penta?uoro; benzyl, Cl-lzCF2CF2CF3, 1
lower alkyl tetrazolyl-, l-phenyltetrazolyl-, 2-thioxo-3
thiazolindyl, pyridyl, and benzothiazolyl, provided that

tuted carbamates as the active ingredients, methods for
inhibiting the enzyme elastase in animals and humans,

and methods for production of the compounds and

compositions.

when R is paranitrophenyl, R’ is other than tertiary
butyl, benzyl or cyclohexyl, and when X is sulfur, R is

DESCRIPTION OF PREFERRED
EMBODIMENTS
As pointed out above, the invention relates to certain

other than benzyl.
In more preferred and detailed embodiments, the
compounds of the invention may be described by the
following general formulae A or E:

novel substituted carbamate compounds, pharmaceuti
cal compositions containing these compounds, and

methods for use of these pharmaceutical compositions
in the speci?c inhibition of porcine pancreatic elastase
and human leukocyte elastase without affecting the
similar serine dependent proteases, bovine pancreatic
trypsin and chymotrypsin. It is known from the art that 20
proteases from polymorphonuclear leukocytes and
wherein X is oxygen or sulfur and R is selected from the

macrophages, especially elastases (human leukocyte

group consisting of phenyl, ?uorophenyl, nitrophenyl,
l-phenyltetrazolyl, l-lower alkyl tetrazolyl, benzyl,

HL elastase and cathepsin G) appear to be responsible
for the chronic tissue destruction associated with in

?ammation, arthritis and emphysema. During infection
or in?ammation, the normal lung is protected from

proteolytic digestion by the protease inhibitor, ctr-ani
trypsin. This protective mechanism appears to be non
operative in individuals with an al-antitrypsin de?
ciency due to genetic or other causes. Synthetic elastase

25

3-thiazolidinyl, pyridyl, and benzothiazolyl, and R’ is
straight or secondary branch chained alkyl of 2 to 4
carbons, alkenyl of 2 to 4 carbons, and alkynyl of 2 to 4
carbons, provided that when R is p-nitrophenyl, R’ is
other than tertiarybutyl, and when X is sulfur, R is other
than benzyl; and

inhibitors capable of replacing al-antitrypsin are there
fore useful in the treatment of pulmonary emphysema
and related diseases.

According to the present invention, a class of com

pounds containing carbamate functionality and oligo
peptides have been found to be active-site directed in
hibitors of elastase in animals and humans. This class of

compounds therefore provide an opportunity to incor
porate chemical moieties which will optimize the affin
wherein Z is selected from the group consisting of
ity of the inhibitor towards the enzyme, and transfer 40 MeO-Suc-Ala-Ala and CF3CO-Ala-Ala, wherein R' is
and acylating moiety to the active site of the enzyme.
as de?ned above but is preferably isopropyl.
The nature of the acylating moiety could be varied to
It will be noted from the description of the com
optimize the duration of enzymatic inactivation.
pounds that the peptidyl carbamates of this invention
It is theorized that the mechanism of the invention
are those wherein the amino portion contains the oligo
takes advantage of the fact that the carbamate esters 45
peptide and the peptide portion is so chosen as to in
will react with proteases and esterases at the carbonyl

carbon by losing the alkoxy portion and transferring the
carbamylating moiety to the active site of the enzyme.
Decylation will then lead to recovery of enzymatic

activity.
The present invention provides a series of carbamate
compounds which are active in accordance with the
above proposals as elastase inhibitors. These com

pounds are carbamates substituted by oligopeptides and

may generally be described by the following general
formula:

crease the speci?city of the carbamate ester for elastase.
In one embodiment, the compounds of the invention

are prepared by a sequential series of reactions begin
ning with L-proline protected on the ring nitrogen with
ultimate coupling to the peptide. In the ?rst step, an
N-protected proline, e.g., N-t-BOC-L-proline, is re
acted with diazomethane to obtain the diazoketone
followed by treatment with HCL to obtain the chloro

methyl ketone protected L-proline. The chloromethyl
ketone thus obtained is reacted with the appropriate
amine HZNR' to form the protected amine derivative.
The amine is in turn reached with the appropriate chlo
roformate or thiochloroformate and deprotected by
reaction with an acid such as HCl to provide the HCl

salt. This compound is then coupled with Z-Ala-Ala by
the mixed carbonic anhydride method to provide the
wherein Z is selected from the group consisting of
R"O—Suc—where R" is lower alkyl of l to 3 carbon

compounds of the invention. The Z-Ala-Ala com

lected from the group consisting of straight or second
ary branched-chain alkyl of l to 4 carbon atoms, alkenyl
of 1 to 4 carbon atoms, alkynyl of 2 to 4 carbon atoms,

Z=R"O—-Suc, e.g., MeOSuc. These Z-Ala-Ala inter
mediates may be prepared according to the following
scheme:

pounds are obtained by reaction of Ala-Ala with methyl
atoms, and CF3CO-—; X is oxygen or sulfur, R’ is se 65 succinic acid N-hydroxy succinimide ester when

4,643,991
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R.

In conducting these reactions, the L-proline in the
initial step is protected on the ring nitrogen by reaction

As pointed out above, the compounds of the inven

with any suitable protective agent known to the art so
tion may be employed as speci?c active site directed
that reaction will occur on the carboxylic acid portion 25 inhibitors of the enzyme, elastase. For this purpose, the
of the molecule. Preferably, the nitrogen atom in the
compounds are preferably combined with a pharmaceu

ring is protected with a known protective agent, such as
t-BOC. For example, t-BOC-Pro is available commer

cially from Sigma Chemical Company, St. Louis, M0.
The protected proline is reacted with diazomethane by

tically acceptable carrier for administration by injection
or in the oral form. Conventional adjuvants and carriers
may be employed in combination with about 0.001 to
30 2.0 weight percent of the active compound. The com
pounds may be administered to animals or humans at

the method of Penke et al. (B. Penke, J. Czombos, L.
Balaspiri, J. Peters and K. Kovacs, Helv. Chim. Acta.,

dosage amounts ranging from about 1 mg/kg up to
about 10 mg/kg, preferably an average amount of about

53, 1057 (1970). Thereafter, the resulting chloromethyl

ketone is then reacted with the appropriate amine. This 35 6 mg/kg.

The following examples illustrate preferred embodi

reaction is preferably conducted in a solvent solution,
such as a lower alkyl alcohol, and preferably in the

ments of the invention but the invention is not consid
ered to be limited thereto. In the examples and through

presence of an alkali metal iodide. The reactants are

out this speci?cation, parts are by weight unless other
wise indicated.
In synthesis of the compounds of the invention, melt

mixed under cool temperatures and then reacted at 50°
to 75° C. to complete the reaction. The evolved HCl is
neutralized, as with a sodium carbonate solution, and
extracted. This intermediate is then reacted with the
appropriate chloroformate or thiochloroforrnate and

ing points were determined on a Thomas-Hoover Uni
Melt apparatus and are uncorrected. ‘H NMR spectra
were obtained using a Varian EM-360 (60 MHZ) or

deprotected with hydrogen chloride to form the carba 45 EM-390 (90_ MH;) spectrometer. Infrared (IR) spectra
mate portion of the molecule. This molecule is then

were recorded on a Perkin-Elmer 567 spectrophotome

coupled with the peptide portion of the molecule to
form the ?nal product.

ter. Microanalyses were performed by Atlantic Mi
crolab, Inc., Atlanta, Ga. or by Micro Analysis, Inc.,

Wilmington, Del.

This reaction procedure may be illustrated as follows:
50

E

H.

CH N

55

Darmstadt, Germany. All compounds were identi?ed

by spectral data and elemental analysis.
EXAMPLE 1

ii

Methyl Succinic Acid-N-hydroxysuccinimide Ester

t-Boc-UCCHNZ 3%
o
“

or HBr-Ninhydrin spraying. Column chromatography
was carried out using Silica Gel 60 from E. Merck,

t-Boc-UCOH 4'29

_

Reactions were routinely followed by thin layer

chromatography (TLC) using Whatman MK6F silica
gel plates. Spots were detected by UV (254 nm), iodine

Nal

t-Boc UGO-12C] W

To an ice-cooled solution of N-hydroxysuccinimide

(1.15 g, 10 mmol) and methyl succinyl chloride (1.23 ml,
10 mmol) in ethyl acetate (50 ml) was added, dropwise,
triethyl amine (1.4 ml, 10 mmol). The mixture was .
stirred at 4° C. for 10 min and at room temperature for

5 min. Filtration of insoluble materials, followed by the

evaporation of the ?ltrate yielded pale yellow crystals.
(2.1 g, 92%); mp. 86°-88° C.

7
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?ltered. The ?ltrate was evaporated and puri?ed by

EXAMPLE 2

column chromatography (CHCl3/E1OAC; 100:1) to

Methyl Succinyl-L-alanyl-L-alanine

give a yellow oil (1.28 g, 81%). NMR (CDC13) &

Without further puri?cation, the product from Exam
ple 1, (1.48 g, 6.46 mmol), was slowly added to a stirred
solution of L-alanyl-L-alanine (862 mg, 5.38 mmol) and
sodium bicarbonate (452 mg, 5.38 mmol) in water (5 ml)

1.0-1.3 (m, 6H), 1.3-1.5 (m, 9H), 1.7-2.2 (m, 4H),
3.3-3.7 (m, 2H), 4.0-4.7 (m, 4H), 7.1-7.4 (m, 2H),

and acetone (5 ml). The mixture was stirred at room

Phenyl N-(N’-t-Boc-L-Prolyl)Methyl-N-Isopropyl

8.1-8.4 (m, 2H); IR (Film) 1690-1740, 1590, 1520 cm* 1.
EXAMPLE 7

temperature for 4 h, and the acetone evaporated. The
aqueous solution was washed with EtOAC (8 ml), acidi

Carbamate

?ed with citric acid (1.3 g), saturated with NaCl, and

This compound was prepared using the procedure of
Example 6 and the product of Example 5 as starting
material, Yield, 95%; NMR (CDCl3) & 1.1-1.4 (m, 6H),

extracted four times with EtOAc (30 ml). The organic
layers were washed with NaCl solution (3 ml) succes~

sively, combined, dried over anhydrous MgSO4, and

give colorless crystals of methyl succinyl-L-alanyl-L

1.47 (s, 9H), 1.7-2.1 (m, 4H), 3.4-3.7 (m, 2H), 3.8-4.6
(m, 4H), 7.0-7.5 (m, 5H); IR (Film) 1680-1750, 1595
cm-1.

alanine, (920 mg, 62%); m.p. 134°-135° C. NMR
(DMSO-d6)'a 1.16 (d, 3H, J=7 Hz), 1.24 (d, 3H, J =7

EXAMPLE 8

evaporated. The residue was washed with EtOAc to

Hz), 2.40 (t, 4H, J =7 Hz), 3.54 (S, 3H), 4.16 (quintet,
1H, J =7 Hz), 4.29 (quintet), 1H, J =7 Hz), 8.01 (d, 2H,
J =7 Hz) ppm; IR (Nujol) 3280, 1735, 1690, 1630, 1540
cm-1. Analysis calculated for C11H13N206: C, 48.17;
H, 6.61; N, 10.21. Found: C, 48,05; H, 6.65; N, 10.17.

20

p-Nitrophenyl N-(L-Prolymethyl)-N-Isopropyl
Carbamate Hydrochloride
A mixture of the product of Example 6 (1.65 mmol) in
formic acid (5 ml) and 1N solution hydrogen chloride in

EXAMPLE 3

THF (2 ml) was stirred at room temperature for 1 h.
The mixture was evaporated and the oil obtained was

(N-t-Boc-L-prolyl)Diazomethane

triturated with EtzO to give the desired compound as

This compound was prepared according to the
method of Penke et al, Helv. Chim. Acta. 53, 1057

(1970).

30

EXAMPLE 4

(N-t-Boc-L-prolyl)Chloromethyl Ketone

9.55.

Into an ice-cooled solution of the product of Example

EXAMPLE 9

3, (11.0 g) in ether (240 ml), HCl gas was introduced

Phenyl N-(L-Prolylmethyl)-N-Isopropyl Carbamate

until the yellow solution turned colorless. The mixture

was evaporated and puri?ed by column chromatogra
phy (hexane/CHClg; 1:1) to give colorless crystals, (9.8
g, 51.7% from t-Boc-L-proline); m.p. 47°-49° C.; NMR
(CDC13) & 1.47 (s, 9H), 1.8-2.2 (m, 4H), 3.4-3.8 (m,
2H), 4.36 (s, 2H), 4.4-4.8 (m, 1H); IR (Film) 1735, 1690
Cm_1. Anal Calcd for C11H1gClNO3: C, 53.33; H, 732;
n, 5.65; Cl, 14.31. Found: C, 53.46; H, 735; N, 5.56; Cl,

crystals. Yield 68.8%; mp 190°-193° C. (dec); NMR
9DMSO-d6) a 1.14 (d, 6H, J- 6 Hz), 1.6-2.2 (m, 4H),
3.1-4.8 (m, 6H), 7.52 (d, 2H, j-9 Hz), 8.48 (d, 2H, J-9
Hz); IR (Nujol) 1740, 1725, 1615, 1595, 1520 cm‘‘.
Anal. calcd for C15H12ClN3O5: C, 51.69; H, 5.96; N,
11.30; Cl, 9.53. Found: C, 51.52; H, 5.98; N, 11.21; Cl,

Hydrochloride
This compound was prepared using the procedure of
Example
8 but the product of Example 7 as starting
40
material. Yield, 58%; m.p. 207°-208° C. (dec); NMR

(DMSO-d6) & 1.0-1.4 (m, 6H), 1.7—2.2 (m, 4H), 3.0-3.7
(m, 2H), 4.1-4.9 (m, 4H), 7.1-7.7 (m, 5H); IR (Nujol)
1750, 1725, 1600, 1550 cm-1. Anal. Calcd for

14.26.
45

EXAMPLE 5

C16H23ClN2O3: C, 58.80; H, 7.09; N, 8.57; Cl, 10.85.
Found: C, 58.57; H, 7.13; N, '8.54; Cl, 10.92.

N-(N'-t-Boc-L-prolyl)Methyl-N-Isopropylamine

EXAMPLE 10

To an ice-cooled solution of the product of Example
4, (3.0 g, 12.1 mmol) in 95% EtOH (30 ml), was added

p-Nitrophenyl N-(Methy
Succinyl-L-Alanyl-L-Alanyl-L-Prolymethyl)-N-Iso
propyl Carbamate

sodium iodide (1.95 g, 12.8 mmol) and isopropylamine
(10.2 ml, 60 mmol). The mixture was shaken at 65° C.
for 15 h and a saturated NaHCO3 solution was added.
The mixture was extracted into ether, evaporated and

puri?ed by column chromatography (CHC13.CH3OH;
50:1) to give a brown oil, (1.84 g, 56%). NMR (CDC13)
& 1.12 (d, 6H, J=6 Hz), 1.50 (s, 9H), 1.8-2.2 (m, 4H),

To a stirred mixture of methy/succinyl-L-alanyl-L

alanine from example 2 (213 mg, 0.778 mmol) and N

methyl morpholine (86 ul, 0.778 mmol) in THF (2.5 ml)
55 at — 15° to —30° C. was added, dropwise, a solution of

isobutyl/chloroformate (101 ul, 0.778 mmol) in THF(1
ml), and the mixture stirred for 30 min at the same tem

2.5-3.1 (m, 3H), 3.4-3.8 (m, 3H), 4.3-4.6 (m, 1H), IR
(Film) 3330 (br), 1695 (br) cm-l.
EXAMPLE 6

perature. A solution of the product from Example 8,

(0.779 mmol), N-methyl morpholine (0.778 mmol) and
60

bis (trimethylsilyl) acetamide (1 ml in THF (3 ml) was

p-Nitrophenyl
N-(N’-t-Boc-L-prolyl)Methyl-N-Isopropylcarbamate

then added dropwise to the above mixture at —50° C.
The reaction mixture obtained was warmed up gradu
ally stirred at room temperature overnight, diluted with

A solution of p-nitrophenyl chloroformate (0.88 g,
4.34 mmol) in dry THF (10 ml) was added dropwise to
a solution of the product of Example 5, 10.98 g, 3.36

CHC13 (10 ml), successively washed with 10% citric
acid, and 4% NHHCO3 solution and evaporated. The
resulting oil was puri?ed by column chromatography
(CHC13 MeOH, 50:1) to give crystals. Yield, 82%; m.p.
153°-163° C.; NMR (CDC13) & 1.0-1.5 (m, 12H),

mmol) and triethylamine (0.604 ml, 4.34 mmol) in THF
at 5° C. The mixture was stirred at 5° C. for 2 h and

9
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1.8-2.4 (m, 4H), 2.4—2.9 (m, 4H), 3.5-4.0 (m, 2H), 3.83
(s, 3H), 4.2—5.0 (m, 6H), 6.5-7.7 (In, 4H), 8.46 (d, 2H,
J=7 HZ); IR (Nujol) 3350, 1737, 1720, 1688, 1655, 1645,

(6H, <1, J=6 Hz), 1.46 (91-1, s), 1.11-2.2(411, m), 3.4-3.7
(2H, m), 4.10 (3H, s), 40-46 (411, m) ppm IR (Film)

1525 Cm_1. Anal Calcd for C27H37N5010: C, 54.82; H,
6.30; N, 11.84. Found: C, 54.60; H, 6.34, N, 11.73.

c, 49.50; H, 6.84; N, 20.37. Found: c, 49.65; 11, 6.87; N,

1735, 1685, 1670 cm- 1. Anal. Calcd for C17H2gN6O4S:
20.30.

EXAMPLE 1 l

EXAMPLE l6

Phenyl N-(Methyl
Succinyl-L-Alanyl-L-Alanyl-L-Prolyl

l-Methyl-S-tetrazolyl

N-(L-prolylmethyD-N-isopropylthio-carbamate

Methyl)-N-Isopropyl Carbamate '

Hydrochloride

This compound was prepared using the procedure of
Example 10 and the product of Example 9 as starting
material. Yield, 67%; mp. 60°-65° C.; NMR (CDC13) &
0.7-1.4 (m, 12H), 1.7-2.2 (m, 4H), 2.3-2.8 (m, 4H), 3.77

The title compound was prepared by the same
method as that of Example 8 (52% yield).
EXAMPLE l7

(s, 3H), 3.1-3.40 (m, 2H), 4.0-4.8 (m, 6H), 6.1-7.6 (m,
7H); IR (Film) 3300-3500, 1730 (br), 1645 (br), 1530 (br)

l-Methyl-S-tetrazolyl N-(methyl
succinyl-L-alany]-L-alanyl-L-prolylmethyl)-N-iso
propylthiocarbamate

cm*1. Anal. calcd for Cpl-133N403: C, 59.33; H, 7.01;
N, 10.25. Found: C, 59.16; H, 7.06; N, 10.17
EXAMPLE l2

20

(N-t-Boc-L-prolyl) chloromethane

The title compound was prepared by the same
method as that of Example 10. The obtained oil was

crystallized from ethyl acetate-hexane, 21% yield, mp
ll0°-l13° C. NMR (&, CDC13), 0.9-1.5 (12H, 111),
1.8-2.2 (4H, m), 2.4-2.8 (4H, 111), 3.5-3.8 (2H, m), 3.76
(3H, s), 4.10 (3H, s), 4.0-4.9 (6H, m), 6.56 (1H, brd, .1-8
Hz), 7.20 (1H, brd, J =8 Hz), ppm. IR (Film); 3300,

The title compound was prepared in the same manner

as that of Example 4. (76.3% yield from N-Boc-proline).
EXAMPLE 13

N-(N’-t-Boc-L-prolyl)methyl-N-isopropylamine

1735, 1680-1640, 1520 cm-1. Anal. Calcd. for
C23H36N3O7S: C, 48.58; H, 6.38; N, 1970. Found: C,
48.41; H, 6.43; N, 19.58.

To a solution of (N-t-Boc-L-prolyl)chloromethane
(3.0 g, 0.0121 mol) in ether (40 ml) ‘at 5° C. was added
isopropylamine (12 ml). The solution was stirred over

EXAMPLE 18

night in an ice bath and allowed to come to room tem

perature. Precipitated isopropylamine hydrochloride

N-(N'-t-Boc-L-prolyl)methyl-N-cyclopropylamine

was ?ltered off and washed with ether. The ?ltrate was
evaporated in vacuo to give an oil. The oil was puri?ed

The title compound was prepared in a similar manner

by column chromatography (silica gel 45 g, solvent 2%

35 to Example 13 and obtained as an oil, 52.4% yield.

MeOH-CHCl3) to give 216 g of the product as an oil.

NMR (&, CDC13) 0.33 (4H, m), 1.46 (9H, s), 2.0-2.3
(6H, m), 3.3-3.9 (4H, m), 4.40 (1H, m) ppm, IR (Film)
3260, 1720, 1680, 1400, 1160 cm—1.

NMR (&, CDC13), 1.12 (6H, d, J=6 Hz), 1.50 (9H, s),
1.8-2.2 (4H, m), 2.83 (1H, m), 3.3-3.9 (5H, m), 4.30 (1H,
m) ppm; IR (Film) 3330 (br), 1690 cm-1.
EXAMPLE 14

EXAMPLE l9

40

1-Methyl-5-tetraazolyl
N-(N’-t-Boc-L-prolyl)methyl-N-cyclopropyl

l-Methyl-S-tetrazolyl thiochloroformate

thiocarbamate

A solution of triethylamine (0.647 ml, 4.64 mmol) in
THF (2 ml) was added dropwise to a mixture of l-meth

The title compound was prepared in a similar manner
yl-5-mercaptotetrazole (450 mg‘, 3.87 mmol) in the THF 45 to Example 15 as a powder, 30% yield. m p 144°-148°

(5 ml) and 12.5% phosgene in benzene (4.7 ml, 6 mmol)

C. NMR (&, CDC13); 1.00 (4H, m), 1.46 (9H, s), 1.7-2.3
(4H, m), 2.96 (1H, m), 3.53 (2H, m), 4.06 (3H, s), 4.30

at 0°-5° C. The mixture was stirred at 0°—5° C. for 30
min and at room temperature for 2 h, followed by ?ltra
tion of the mixture. The ?ltrate obtained was evapo

(3H, m) ppm. IR (Film) 1730, 1680, 1480, 1400 cm—l.
Anal. Calcd. for C|7H26N604S: C, 49.75; H, 6.34; N,
20.48. Found: C, 49.49; H, 6.39; N, 20.34.

rated go give 0.62 g (89.7%) of pale brown crystals of
the title compound NMR (CDC13) & 4.23 (S, 3H), IR
(Film) 1770 cm-1.
EXAMPLE 15 l-Methyl-S-tetrazolyl

EXAMPLE 2O

l-Methyl-S-tetrazolyl
N-(L-prolylmethyl)-N-cyclopropylthiocarbamate
Hydrochloride

N-(N’-t-Boc-L-prolyl)methyl-N-isopropylthiocarba
mate

To a solution of the product of Example 13 (1.95 g,

The compound of Example 39 (0.82 g, 2 mmol) was
dissolved in ethyl acetate (30 ml). HCl gas was passed

-7.2 mmol) and triethylamine (1.30 ml, 9.36 mmol) in
THF (15 ml) at 5° C. was added a suspension of l-meth

through the solution at room temperature for 5 minutes.
After evaporation of the solvent, the residue was tritu

yl-5-tetrazolyl thiochloroformate from Example 15,
(1.67 g, 9.36 mmol) in THF(10 m1) over 4 min, and the

rated with ether to give a powder 80% yield, mp

mixture was stirred for 1 hour at 5° C. CHC13. The

organic layer was dried over anhydrous MgSO4 and
evaporated in vacuo to give an oil. The oil was puri?ed

by column chromatography (silica gel 40 g) using
CHC13 as an eluent to give 1.86 g of the product as an

oil, 74% yield. The oil was crystallized from ethyl ace
tate-hexane mp 145°-150° C. NMR (&, CDC13) 1.30

65

l44°-148° C. NMR (&, DMSO-d?): 1.00 (4H, m),
1.5-2.0 (4H, m), 3.20 (3H, m), 4.00 (1H, m), 4.07 (3H, s),
460 (2H, m) ppm. IR (Nujol) 1725 1670, 1260 cm—1.
Anal. Calcd. for C12H19ClN6O2S: C, 41.78; H, 5.48; N,
24.24; S, 9.23. Found: C, 41.60; H, 5.55; N, 24.17; S,
10.32.
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EXAMPLE 21

cm- 1.

l-Methyl-S-tetrazolyl N-(methyl

succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-cyclo
propylthiocarbamate

EXAMPLE 27

5 P-Nitrophenyl N-(L-prolylmethyl)-N-propylcarbamate

Hydrochloride

The title compound was prepared in a manner similar

The title compound was prepared in the same manner

to Example 17. The product powder was obtained in
60.8% yield, mp 107°-l09° C. NMR (&, CDCl3) 1.00

as previous Example 8. The compound of Example 26
(0.72 g, 1.65 mmol) was dissolved in a mixture of formic

(4H, m), 1.36 (6H, d, J =6 Hz), 1.8-2.4 (4H, m), 2.63
(4H, m), 3.0 (1H, m), 3.66 (2H, m), 3.73 (3H, s), 4.08
(3H, s), 4.3-4.9 (5H, m) ppm. IR (CHC13) 3300-3400,

acid (10 ml) and 1N HCl in THF (10 ml). The solution
was stirred at room temperature for 3 hours. Evapora
tion of the solvent gave a residue which was triturated

1730, 1710, 1680, 1510 cm“. Anal. Calcd. for

with ether to give a powder. The powder was collected
and washed with ether to give 0.49 g of the product.
79.8% yield. m p 155°-160° C. NMR (&, DMSO-d6) 0.9

C23H34N307S: C, 48.76; H, 6.05; N, 19.77. Found C,
48.56; H, 6.07; N, 19.57.

(3H, br, t, J =9 Hz), 1.1-2.2 (6H, m), 3.0-3.7 (4H, m),
4.3-4.8 (3H, m), 7.46 (2H, d, J=9 Hz), 8.37 (2H, d, J=9
Hz) ppm. IR (Nujol) 3400, 1720, 1610, 1590, 1520 cm* 1.

EXAMPLE 22

N-(N-t-Boc-L-prolyl)methyl-N-propylamine
The title compound was prepared in a similar manner

to Example 13 as an oil, 54% yield. NMR (&, CDCl3) 20

succinyl-L-alanyl-L-alanyl-L-prolylmethyl)
N-propylcarbamate
25

l-Methyl-S-tetrazolyl
The title compound was prepared in a similar way to
30

P-Nitrophenyl

N-(N'-t-Boc-L-prolyl)methyl-N-cyclopropylcarbamate
The title compound was prepared in the same way as
that of Example 6 as an oil. 45% yield, NMR (&,

l-Methyl-S-tetrazolyl
N-(L-prolylmethyl)-N-propylthio carbamate
40

The title compound was prepared in a similar manner

CDC13) 0.86 (4H, m), 1.50 (9H, s), 1.7-2.5 (4H, m), 3.0
(1H, m), 3.56 (2H, m), 4.40 (3H, m), 7.43 (2H, brd, J =9
Hz), 8.33 (2H, br, d, J =9 Hz) ppm IR (?lm) 1740, 1720,
1700, 1610, 1590, 1390, 1210 cut-1.
EXAMPLE 30

to Example 20, 84% yield, m p l07°-112° C. NMR (&,

DMSO-d6) 1.0 (3H, m), 1.2-2.0 (6H, m), 3.0 (2H, m),
4.07 (3H, s), 4.25-5.0 (5H, 111) ppm. IR (Film) 3350,

7.1-7.63H, m), 8.30 (2H, br, d, J=9 Hz) ppm. IR (?lm)
3320, 1740, 1650, 1580, 1550 cm-l.
EXAMPLE 29

EXAMPLE 24

Hydrochloride

The title compound was prepared in the same manner
as that of Example 10. 20.1% yield, m p l58°-l61° C.

NMR (&, CDC13) 0.96 (3H, m), 1.36 (6H, br, (1, J :65
Hz), 1.5-2.3 (6H, m), 2.63 (4H, br, s), 3.2-4.0 (4H, m),
3.70 (3H, 5), 4.2-50 (5H, m), 7.0 (1H, br, 11, J :65 Hz),

N-(N’-t-Boc-L-prolyl)methy1-N-propyl thiocarbamate
Example 15 to give crystals, 23.5% yield. mp l12°-114°
C. NMR (&, CDC13) 1.00 (3H, t, J =7 Hz), 14.6 (0H, s),
1.6-2.3 (6H, 111), 32-3.? (4H, m), 4.10 (3H, s), 4.30 (3H,
m) ppm. IR (Film) 1730, 1680, 1380, 1160 cm-1. Anal.
Calcd. for C17H2gN6O4S: C, 49.51; H, 6.79; N, 20.38.
Found: C, 49.23; H, 6.84; N, 20.30.

EXAMPLE 28

P-Nitrophenyl N-(methyl

0.90 (3H, t, J =7 Hz), 1.43 (9H, s), 1.6-2.3 (6H, m), 2.67
(2H, t, J=7 Hz), 3.3-3.7 (4H, m), 4.33 (1H, m) ppm. IR
(Film) 3300, 1710, 1690, 1380 cm-1.
EXAMPLE 23

12

m), 8.30 (21-1, 111) ppm. IR (Film) 1740, 1700, 1670, 1610

P-Nitrophenyl
45

1740, 1680 cm—1.

N-(L-prolylmethyl)-N-cyclopropylcarbamate
hydrochloride)

EXAMPLE 25

HCl gas was passed through a solution of the product

of Example 29 (1.3 g, 3.0 mmol) in ether (40 ml) for 6

l-Methyl-S-tetrazolyl N-(methyl

succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-propyl

50

thiocarbamate

to Example 17, mp, 138°-140° C. 22.3% yield. IR (Film)
3300, 1735, 1650, 1530, 1170 cm“. NMR (&, CDC13)
1.00 (3H, br, t, J=7 Hz), 1.40 (6H, d, J=7 Hz) 1.2-1.8

EXAMPLE 26

collected and washed with ether to give the product

(0.7 g), 63% yield. m p 150° C. (dec). NMR (&, CDC13),
0.81 (4H, m), 1.7-2.3 (4H, m), 2.90 (1H, m) 3.23 (2H, m),
4.60 (3H, m), 7.46 (2H, brd, J =9 Hz), 8.36 (2H, d, J =9
Hz). Anal. Calcd for C16H20C1N3O5: C, 51.96; H, 5.44;
N, 11.36. Found, C, 51.72; H, 5.48; N, 11.30.

The title compound was prepared in a similar manner

(2H, m), 2.07 (4H, m), 2.66 (4H, m), 3.50 (2H, m), 3.70
(3H, s), 4.10 (3H, s), 4.2-5.0 (5H, m), 6.9 (1H, m), 7.4
(1H, m) ppm. Anal. calcd. for C23H36NgO7: C, 48.58; H,
6.38; N, 19.71. Found: C, 48.37; H, 6.38; N, 19.64.

min at room temperature. Precipitated amine salts were

EXAMPLE 31

P-Nitrophenyl N-(methyl

60

succinyl-L-alanyl-L-analyl-L-proly1methyl)-N-cyclo
propylcarbamate

p-Nitrophenyl
N-(N'-t-Boc-L-prolyl)methyl-N-propylcarbamate

The title compound was prepared in the same manner
as Example 10 and was obtained as a powder, 61%

The title compound was prepared in the same way as

1640, 1590, 1520 cmrl. NMR (&, CDC13) 0.83 (4H, m),
1.40 (6H, d, J =7 Hz), 1.8-2.3 (4H, m), 2.60 (4H, m), 3.0
(1H, m), 3.60 (2H, m), 3.70 (3H, s), 4.2-5.0 (5H, m), 6.38
(1H, br, d, J=8 Hz), 7.03 (1H, br, t, J=8 Hz), 7.36 (2H,

that of Example 6 to recover an oil, 51.7% yield. NMR

(&, CDC13) 0.93 (3H, br, t, J =7.5 Hz), 1.46 (9H, s),
1.5-2.5 (6H, m), 3.50 (4H, m), 4.30 (3H, m), 7.40 (2H,

yield. m p 154°-158° C. IR (?lm) 3340, 1740, 1690, 1655,
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d, J =9 Hz), 8.30 (2H, d, J =9 Hz). Anal. Calcd. for
C27H35N5O10: C, 55.00, H, 5.98; N, 11.88. Found C,

(3H, s), 4.2—5.0 (5H, m), 6.50 (1H, b1‘, d, J =7 Hz), 7.10

54.80; H, 5.99; N, 11.76.

C24H33N307S: C, 49.47; H, 6.57; N, 19.23. F0und=C,
49.52; H, 6.58; N, 19.08.

(1H, br, d, J =7 Hz) ppm. Anal Calcd. for

EXAMPLE 32

N-(N'-t-Boc-L-prolyl)methyl-N-butylamine

EXAMPLE 36

To a solution of the product of Example 12 (2.8 g,
0.0113 mol) in ether (70 ml) at 5° C. was added n-butyla

l-Phenyl-S-tetrazolyl
N-(N'-t-Boc-L-prolyl)methyl-N-isopropylthiocarba
mate

mine (8.2 ml 0.0831 mol). The solution was stirred at 5°
C. for 5 hours. Precipitated salts were ?ltered and
washed with ether. The ?ltrate was evaporated in
vacuo to give an oil. The oil was purified by column

The title compound was prepared in a similar manner

as that of Example 15 as an oil, 73.8% yield. IR (Film)

1735, 1690, 1590, 1495, 1400 cm-L NMR (&, CDClg),
1.17 (6H, d, J =7 Hz), 1.47 (9H, s), 1.95 (4H, m), 3.46

chromatography (silica gel 15 g, solvent 2% MeOH
CHC13) to give 3.2 g of the product as an oil. IR (Film)

(2H, m), 3.9-4.6 (4H, m), 7.70 (5H, s).

3300, 1690, 1380 cm-1. NMR (&, CDC13) 1.0 (3H, m),
1.50 (9H, s), 1.2-1.8 (4H, m), 1.8-2.2 (4H, m), 2.60 (2H,
m), 3.1-3.9 (5H, m), 4.33 (1H, m).

EXAMPLE 37

l-Phenyl-S-tetrazolyl
N-(L-prolylmethyl)-N-isopropylthiocarbamate
Hydrochloride

EXAMPLE 33

l-Methyl-S-tetrazolyl

The title compound was prepared in a similar manner

N-(N'-t-Boc-L-proly1)methyl-N-butyl thiocarbamate

‘to Example 20 as an amorphous powder 46.2% yield.
IR (Nujol) 3400, 1760, 1730, 1670, 1590 cm-1. NMR

The title compound was prepared in a manner similar

to Example 15, 35.1% yield, mp 125°-128° C. IR

(&, DMSO-dg) 1.13 (6H, m), 2.0(41-1, m), 3.30 (2H, m),

(Nujol), 1735, 1670, 1170, 1120 cm~1, NMR (&,
CDC13), 0.96 (3H, brt, J =5 Hz), 1.46 (9H, s), 1.2-1.8
(4H, m), 2.0 (41-1, m), 3.2-3.7 (4H, m), 4.07 (3H, s),

3.8-4.8 (4H, m), 7.7—8.0 (5H, m) ppm.
EXAMPLE 38

4.2-4.6 (3H, m) ppm. Anal. Calcd. for C13H30N6O4S. C,

l-Phenyl-S-tetrazolyl N-(methyl

50.69; H, 7.09; N, 19.70. Found: C, 50.75; H, 7.14; N,

succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-iso
propylthiolcarbamate

19.66.
EXAMPLE 34

l-Methyl-S-tetrazolyl
N-(L-prolylmethyl)-N-butylthiolcarbamate
Hydrochloride

The title compound was prepared in a similar manner

to Example 35, 44.0% yield, mp 103°—l08° C. IR
35

The title compound was prepared in a similar manner

to Example 20, 91.9% yield, m p 120°-129° C. IR

(Nujol) 3350, 1735, 1665,1560, 1200 cm". NMR (&,
DMSO-d6) 0.96 (3H, m), 1.2-2.3 (8H, m), 3.0-3.6 (4H,
m), 4.06 (3H, s), 4.4-5.0 (3H, m). Anal. Cacld. for
C13H23CIN6O2S; C, 43.03; H, 6.39. Found C, 43.10; H,
6.62.

(Nujol) 3340, 1735, 1680, 1655, 1530 cm-1. NMR (&,
CDC13), 0.8-1.7 (12H, m), 2.03 (4H, m), 2.60 (4H, m),
3.66 (2H, m), 7.60 (5H, s) ppm. Mal. Calcd. for

C23H38N307S: C, 53.32; H, 6.07; N, 17.77. Found: C,
53.17; L H, 6.15; N, 17.68.
EXAMPLE 39

N-(N'-t-Boc-L-prolyl)methyl-N~allylamine
The title compound was prepared in a similar manner

.

EXAMPLE 35

l-Methyl-S-tetrazolyl N-(methyl
succinyl-L-alanyl-L-alanyl-L-prolymethyl)-N-butylthi
ocarbamate

To a solution of the product of Example 2, (0.428 g,

0.00173 mol) and N-methyl morpholine (0.175 g,
0.00173 mol) in THF (3 ml) at —15° C. was added a 50

solution of isobutyl chloroformate (0.236 g, 0.00173
mol) in THF (1.6 ml). The mixture was stirred at — 15°
C. for 10 minutes. To the mixture at — 15° C. was added

a solution of the product of Example 34, (0.57 g, 0.00157

mol) and N-methyl-morpholine (0.159 g) in CH3CN (5
ml). The mixture was stirred at 5° C. for 1.5 hours and
stored at 5° C. overnight. The reaction mixture was
diluted with CHC13, washed with 10% aq. citric acid,
water and saturated NaCl solution, and dried over an

hydrous MgSO4. Evaporation of the solvents gave an
oily residue which was puri?ed by column chromatog
raphy (silica gel 16 g, solvent: 2% MeOH-CHCl3) to
give 0.37 g of the product as an oil. The oil was crystal

lized from ethyl acetate-hexane to give 0.27 g of the
product, mp 140°-'-l45° C. 29.5% yield. IR (Nujol) 3340,

1730, 1690, 1655, 1630, 1535 cm—1. NMR (8: CDC13)
1.00 (3H, m), 1.2-1.8 (4H, m), 1.37 (6H, d, J =7 Hz), 2.07
(4H, m), 2.63 (4H, m), 3.3-3.9 (4H, m), 3.73 (3H, s), 4.10

as that of Example 13 as an oil, 55.9% yield IR (Film)
3320, 1700, 1400, 1160 cm-1. NMR (&, CDC13) 1.46 '

(9H, s), 2.00 (4H, m), 3.30 (2H, d, J=5.5 Hz), 3.4-3.s
(4H, m), 4.40 (1H, m), 5.044 (2H, 111), 5.5-6.3 (1H, m)
EXAMPLE 40

l-Methyl-S-tetrazolyl
N-(N’-t-Boc-L-prolyl)methyl-N-allylthiocarbamate
The tile compound was prepared in a similar manner

as that of Example 15, as a powder, 39.5% yield, mp
124°—126° C. IR (CHC13) 1735, 1685, 1160 cm-1. NMR

(&, CDCl3): 1.47 (9H, s), 2.0 (4H, m), 3.50 (2H, m), 4.10
(3H, s), 4.0-4.6 (5H, 111), 5.1-5.5 (2H, m), 5.6-6.4 (1H, m)
ppm; Anal. Calcd for C17H26N6O4S C, 49.74, H, 6.38;
N, 20.47 Found: C, 49.50; H, 6.45; N, 20.37.
EXAMPLE 41
il-Methyl-S-tetrazolyl

-

N-(L-proly1methyl)-N-allylthiocarbamate

Hydrochloride
The title compound was prepared in a similar manner
as Example 20 as a powder, 93.8% yield, NMR (&,

DMSO-D6), 1.90 (4H, m), 3.20 (2H, m), 4.07 (3H, s),
3.9-4.9 (5H, m), 5.0-5.6 (2H, m), 5.7-6.3 (1H, m) ppm.
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1.43 (9H, s), 1.96 (4H, m), 3.3-4.0(61-1, m), 4.33 (1H, m),

EXAMPLE 42

7.36 (5H, s) ppm.

l-Methyl-S-tetrazolyl N-(methyl
succinyl-L-alanyl-L-alany1-L-prolylmethyl)-N-allylthi

EXAMPLE 48

P-Nitrophenyl
N-(N’-t-Boc-L-prolyl)methyl-N-phenylmethylcarba

ocarbamate
The title compound was prepared in a similar manner
as Example 17 as a powder. 24.3% yield, mp 143°—l45°

mate

C. IR (Film) 3340, 1735, 1660, 1530, 1450 cm—1. NMR
(&, CDC13), 1.40 (6H, d, J =I-Iz), 2.10 (4H, m), 2.66 (4H,

The title compound was prepared in a similar manner

as that of Example 6 as an oil, 56% yield. IR (CHC13):

m), 3.73 (3H, s), 3.6-3.8 (2H, m), 4.10 (3H, s), 4.1-5.0
(7H, m), 5.1-5.6 (2H, m), 5.6-6.3 (1H, m), 6.8 (1H, br, d,

1730, 1690, 1615, 1595, 1525 cm—1. NMR (&, CDC13):
1.43 (9H, s), 1.7-2.3 (4H, m), 3.50 (2H, m), 4.0-5.0 (5H,
m), 7.37 (7H, m), 8.33 (2H, d, J =0 Hz) ppm.

J =7 Hz), 7.20 (1H, 111) ppm. Anal. Calc. for

C23H34N307S: C, 48.75; H, 6.05; N, 19.78. Found C,
48.51, H, 6.08, N, 19.68.

EXAMPLE 49

P-Nitrophenyl
N-(L-prolylmethyl)-N-phenylmethylcarbamate
Hydrochloride

EXAMPLE 43

N-(N’-t-Boc-L-prolyl)methyl-N-(2-methyl)proplya
mine

The title compound was prepared in a similar manner
The title compound was prepared in a similar manner 20 as that of Example 30 was a powder. 38.4% yield mp

as Example 13 as an oil, 69.75 yield. NMR (&, CDCl3),

136°-142° C. IR (Nujol) 3400, 1730, 1670, 1590 cm-1.
NMR (&, DMSO-d6), 2.00 (4H, m), 3.3 (2H, m), 4.2-5.0
(5H, m), 7.3-7.4 (7H, m), 8.33 (2H, d, J =9 Hz) ppm.

0.93 (6H, d, J=6 Hz), 1.46 (9H, s), 1.3-1.6 (1H, m), 2.0
(4H, m), 2.43 (2H, m), 3.3-4.3 (4H, m), 4.40 (1H, m)
ppm. IR (Film) 3340, 1700, 1470, 1400 cm"1.
EXAMPLE 44

P-Nitrophenyl N-(methyl
succinyl-L-alanyl-L-alanyl-L~prolylmethyD-N-phenyl
methylcarbamate

P-Nitrophenyl
~ N-(N’-t-Boc-L-prolyl)methyl-N-(2-methyl)lpropylcar

bamate
The title compound was prepared in a similar manner
as Example 6 as an oil, 93% yield. IR (Film) 1730, 1615,

EXAMPLE 50

25
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The title compound was prepared in a similar manner
as that of Example 10 as a powder, 39.6% yield mp

14l°-l43° C. IR (Nujol) 3340, 1730, 1690, 1660, 1630,

1595, 1525 cm-1. NMR (&, CDCL3), 0.96 (6H, d, J =6

1520 cm—1. NMR (&, CDCl3), 1.2-1.8 (6H, m), 2.00

Hz), 1.43 (9H, s), 1.3-1.6 (1H, m), 2.0 (4H, m), 3.1-3.8
(4H, m), 4.1-4.6 (3H, m), 7.3 (2H, br, d, J =9 Hz), 8.33

(4H, m), 3.70 (2H, m), 4.2—5.0 (7H, m), 6.46 (1H, m),
3.70 (3H, s), 3.70 (2H, m), 4.2-5.0 (7H, m). 6.46 (1H, br,

(2H, d, J =8 Hz) ppm.

P-Nitrophenyl N-(L-prolylmethyD-N-(2-methyl)
propylcarbamate Hydrochloride

d, J =7 Hz), 7.10 (1H, br, d, J =7 Hz), 7.3-7.6 (7H, m),
8.33 (2H, d, J =9 Hz) ppm. Anal. Calcd. for
C31H37N5O10. C, 58.21; H, 5.79; N, 10.95. Found: C,
57.97; H, 5.86; N, 10.89.

The title compound was prepared in a similar manner
as that of Example 30 as a powder, 47% yield, mp

N (N'-t-Boc-L-prolyl)methyl-N-cyclohexylamine

EXAMPLE 45

135°—149° C. IR (Nujol) 3500, 1740, 1710, 1615, 1595
cm-1. NMR (&, DMSO-d6), 0.95 (6H, d, .1 =6 Hz),
1.3—2.2 (7H, m), 3.0-3.6 (4H, m), 4.1-4.8 (3H, m), 7.43
(2H, br, d, dd, J =2, 9 Hz), 8.36 (2H, d, J =9 Hz) ppm.

EXAMPLE 51
The title compound was prepared in a similar manner
45 as that of Example 13 as an oil, 43.9% yield. IR (Film)

3320, 1690, 1390 cm-1. NMR (&, CDC13), 0.9-2.5 (15H,
m), 1.47 (9H, s), 3.3-3.9 (4H, m), 4.33 (1H, in), ppm.

EXAMPLE 46

p-Nitrophenyl N-(methyl
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-(2
methyl)propylcarbamate

EXAMPLE 52
50

P-Nitrophenyl

N-(N '-t-Boc-L-pro1yl)methyl-N-cyclohexylcarbamate)
The title compound was prepared in a similar manner

The title compound was prepared in a similar manner
as that of Example 10 as a powder, 57.7% yield mp

as that of Example 6 as an oil, 80.1% yield IR (Film)

177°-179° C. IR (Nujol) 3350, 1735, 1695, 1660, 1635,
1595 cm—1. NMR (&, CDCl3): 0.96 (6H, d, J =7.5 Hz),

1725, 1690, 1612, 1590, 1520 cm—1. NMR (&, CDC13),
0.9-2.3 (14H, m), 1.47 (9H, s), 3.3-4.0 (3H, m), 4.1-4.6
(3H, m), 7.13 (2H, dd, J=3.5, 9 Hz), 8.30 (2H, d, J=9

;b 1.35 (6H, d, J =7 hz), 1.5-2.0 (1H, m), ‘2.0 (4H, m),
2.60 (4H, m), 3.30 (2H, m), 3.70 (3H, s), 3.70 (2H, m),
4.1-5.0 (5H, m), 6.50 (1H, br, d, J=7 Hz), 7.10 (1H, m),
7.30 (2H, d, J=9 Hz), 8.30 (2H, d, J=9 Hz) ppm. Anal.
Calcd. for C23H39N5010: C, 55.53; H, 6.44; N, 11.57.
Found: c, 55.29; H, 6.55; N, 11.46.
EXAMPLE 47

HZ) PPm-

-

EXAMPLE 53

P-Nitrophenyl
N-(L-prolylmethyl)-N-cyclohexylcarbamate

Hydrochloride

N-(N'-t-Boc-L-prolyl)methyl-N-phenylmethylamine

The title compound was prepared in a similar manner
as that of Example 30 as a powder, 77.3% yield, mp

The title compound was prepared in a similar manner
as that of Example 13 as an oil, 63.5% yield. IR (Film)

NMR (&, DMSO-dg) 1.1-2.6 (14H, m), 3.3-4.9 (6H, m),

3310, 1700, 1605, 1585, 1400 cm-‘l. NMR (&, CDC13),

1.47 (2H, dd, J =3.5, 9 Hz), 8.43 (2H, d, J =9 Hz) ppm.

l46°-158° C. IR (Nujol) 1720, 1612, 1595, 1515 cm-l.

4,643,991
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EXAMPLE 54

EXAMPLE 60

P-Nitrophenyl N-(methyl
succinyl-L-alanyl-L-alanyl~L-prolylmethyl)-N
cyclohexylcarbamate

Heptalluorobutyl N-(methyl
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-iso
propylcarbamate

The title compound was prepared in a similar manner
as that of Example 10 as a powder, 62.9% yield mp

This compound was prepared following the proce
dure in Example 10: Yield, 43%; mp l65°-166° C.;
NMR (CDC13) & 1.16 (d, 6H, J=7 Hz), 1.38 (d, 6H, J-7

l50°-154° C. IR(Nujol) 3345, 1735, 1690, 1655, 1595

Hz), 1.9-2.3 (m, 4H), 2.5-2.8 (m, 4H), 3.75 (S, 3H),
3.6-4.0 (m, 2H), 4.21 (S, 2H), 4.0-5.0 (m, 6H), 6.46 (d,
1H, J=7 Hz), 7.08 (d, 1H, J=7 Hz); IR (nujol) 3350,
1735, 1690, 1655, 1640, 1525 cm-1. Anal. calcd. for
C25H35N4F7Og: C, 46.01; H, 5.41; N, 8.59. Found: C,
45.89; H, 5.42; N, 8.54.

cm~1. NMR(&, CDC13), 1.2-2.4(14H, m), l.40(6H, d,
J =7.5 Hz), 2.66(4H, m), 3.73(3H, s), 3.5-5.0(8H, m), 6.4
(1H, m), 7.0(1H, m), 7.4(2H, d, J =9 Hz), 8.33(2H, d,
J'=9 HZ). Anal. Calcd. for C30H4|N5010: C, 57.05; H,
6.49; N, 11.09. Found: C, 56.87; H, 6.54; N, 11.00
EXAMPLE 55

EXAMPLE 61

Penta?uorophenyl-N-(N'-t-Boc-L-prolyl

S-Benzyl

methyl~N-isopropylcarbamate

N-(N’-t-Boc-L-prolyl)methyl-N-isopropylthiocarba
mate

This compound was prepared according to the proce 20

dure described in Example 6; NMR (CDC13) & 1.1-1.4

This compound was prepared according to the proce

(m, 6H), 1.48 (S, 9H), 1.9-2.3 (m, 4H, 3.4-3.8 (m, 2H),
4.2-4.7 (m, 4H); IR (Film) 1750, 1690, 1515 cm—l-'.

dure described in Example 6 starting with S-benzyl
chlorothioformate (J. J. Willard and E. Pacsu, J. Am.

Chem. Soc., 82, 4317 (1960): NMR (CDC13) & 1.18 (d,
6H, J=7 Hz), 1.50 (s, 9H), 1.s-2.4 (m, 4H), 34-31; (m,
2H, 4.26 (S, 2H, 4.2-4.6 (m, 4H), 7.45 (S, 5H); IF (Film)
1740, 1690, 1640 crn-l.

EXAMPLE 56

Pentalluorophenyl-N-(L-prolylmethyl)-N-isopropyl
carbamate hydrochloride
This compound was prepared according to the proce
dure described in Example 8: mp l89°-l90° C.; NMR

(DMSO-d@) & 1.0—1.3 (m, 6H), 1.7-2.3 (m, 4H), 3.1-3.5
(m, 2H), 4.0-4.9 (M, 4H); IR (Nujol) 1750, 1515 cmrl.
Anal. calcd. for C|6H1gN2ClF5O3: C, 46.11, H, 4.35; N,
6.72, Cl, 8.50. Found: C, 45.94; H, 4.38; N, 6.66; Cl, 8.67.

EXAMPLE 62
30

This compound was prepared according to the proce- '

dure described in Example 8: mp l93°-l94° C.; NMR

(DMSO-d(,) & 1.10 (d, 6H, J =7 Hz), 1.6-2.3 (m, 4H),
3.0—3.5 (m, 2H), 4.6 (S, 2H), 4.46 (S, 2H), 4.2-4.8 (m,

EXAMPLE 57

Penta?uorophenyl N-(methyl
succinyl-L-analyl-L-alanyl-L-prolymethyl)-N-isopro
pyl-carbamate

2H), 7.41 (S, 5H), 9.7 (hr, 2H), IR (Nujol) 1745, 1635,
1545 cm-1.

This compound was prepared according to the proce 40
dure described in Example 10: yield, 44%; mp

l52°—l54° C.; NRM (CDC13) & 1.0-1.5 (m, 12H),
1.8-2.3 (m, 4H), 2.5-2.8 (m, 4H), 3.4-4.0 (m, 2H), 3.75
(S, 3H), 4.0-5.0 (m, 6H), 6.2-7.4 (br, 2H), IR (Nujol)
3350, 1765, 1740, 1690, 1660, 1640, 1520 cm—l. Anal.
calcd for C27H33N4F403: C, 50.94, H, 5.22; N, 8.80.
Found: C, 50.85; H, 5.26; N, 8.78.
EXAMPLE 58

Hepta?uorobutyl
N-(N'-t-Boc-L-prolyl)methyl-N-isopropyl carbamate
This compound was prepared following the same

procedure as in Example 6: NMR (CDCl3) & 1.13 (d,

6H, J-7 Hz), 1.49 (S, 9H), 1.8-2.2 (m, 4H), 3.4-3.7 (m,
2H), 4.0-5.0 (m, 6H); IR (Film) 1690-1740 cmrl.
EXAMPLE 59

S-Benzyl
N-(L-prolylmethyl)-N-isopropylthiocarbamate
hydrochloride

EXAMPLE 63

S-Benzyl N-(Methyl suc'cinyl
-L-alanyl~L-alanyl-L-prolylmethyl)-N-isopropylthi
ocarbamate

This compound was prepared according to the proce

dure described in Example 10: yield, 41%; mp
125°-127° C.; NMR (CDC13) & 1.0-1.5 (m, 12H),
1.7-2.3 (m, 4H), 2.4-2.8 (m, 4H), 3.4-3.9 (m, 2H), 3.80

(S, 3H)<4.0-4.9 (m, 9H), 7.50 (S, 5H): IR (Nujol) 3360,
50 ‘1735,

1680, 1655, 1640, 1530 cm-‘l. Anal. calcd. for

C28H4ON4O7S: (C, 58.23; H, 6.99, N, 9.71, S, 5.56
Found: C, 58.23, H, 7.00, N, 9.69, S, 5.55.
EXAMPLE 64

N-(N'-t-Boc-L-prolyl)methyl-N-methylamine
Sodium iodide (635 mg, 4.23 mmol) and 40% me

thylaine aqueous solution (6.9 ml, 80.6 mmol) were
added to an ice-cooled solution of product from Exam

ple 4 (1.0 g, 4.03 mmol) in ethanol (10 ml). The mixture
was shaken in a steel bomb at 65° C. for 12 h and the
carbamate hydrochloride
solvent evaporated. Saturated solutions of NaHCO3 (5
This compound was prepared following the proce
ml) and NaCl (5 ml) were added to the residual mixture.
dure in Example 8; mp l49°-150° C.; NMR (DMSO-d6)
The resulting mixture was extracted into ether, evapo
& 1.11 (d, 6H, J-7 Hz), 1.7-2.3 (m, 4H), 3.0-3.4 (m, 2H),
rated and puri?ed by silica gel column chromatography
3.9-5.2 (m, 4H), 4.40 (S, 2H), 9.7 (hr, 2H); IR(Nujol) 65 (CHCl3: CH3OH, 50:1) to give 0.29 g (29.7%) of the
3410, 1745, 1710 cm-1. Anal. calcd for
title compound. NMR (CDC13) & 1.40 (s, 9H), 1.7-2.1
C14H20N2ClF7O3: C; 38.86; H, 4.66; N, 6.47; CI, 8.19.
(m, 4H), 2.40 (s, 3H), 3.3-3.7 (m, 4H), 4.1-4.5 (m, 1H),
IR (Film) 3340 (br), 1695 (br) c-l.
Found: C, 38.58; H, 4.68; N, 6.43; Cl, 8.20.

Heptafluorobutyl N-(L-prolylmethyl)-N-isopropyl
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9 m, 5H), 6.2-6.7 (m, 1H), 6.9—7.7 (m, 3H), 8.0-8.6 (m,
EXAMPLE 65
2H); IR (CHC13) 3300, 1735, 1640, 1590, 1520 cm-1.
p-Nitrophenyl
Anal. Calcd. for CHI-139015010: C, 55.53; H, 6.49; N,
N-(N-t-Boc-L-prolylmethyD-N-methylcarbamate
11.56. Found: C, 55.42; H, 6.54; N, 11.51.
This compound was prepared in a manner similar to 5
EXAMPLE 72
that for Example 6: yield 52%, NMR (CDC13) & 1.49 (s,
9H), 1.8-2.2 (m, 4H), 3.09-3.21 (br. s, 3H), 3.4-3.8 (m,
N-(N'-t-Boc-L-prolyl)methyl-N-isopropyl-2-thioxo-3

2H), 4.3-4.6 (m, 3H), 7.2-7.0 (m, 2H), 8.2-8.5 (m, 2H),
IR (Film) 1740-1670, 1615, 1590, 1520, 1497 cm-l.

thiazolidinecarboxamide
To a solution of N-(N'-t-Boc-L-prolyl)methyl-N-iso

EXAMPLE 66

propylamine (1.7 g, 6.3 mmol) and Et3N (1.09 m], 7.8

p-Nitrophenyl N-(L-prolylmethyl)-N-methylcarbamate
hydrochloride

mmol) in THE (20 ml) at 5° C. was added dropwise a

solution of Compound (88) (1.12 g, 6.2 mmol) in THF
This compound was prepared using the procedure of 15 (20 ml) for 3 min. The solution was stirred at 5° C. for
Example 8: yield 74%; mp l77°-18l° (dec); NMR
45 min and at r.t. for 2 hr. The precipitate was ?ltered
(DMSO-d"’) & 1.7-2.3 (m, 4H), 2.9-3.7 (m, 5H), 4.4-4.8
off and the ?ltrate was evaporated in vacuo to give an
(m, 3H), 7.3-7.7 (m, 2H), 8.2-8.5 (m, 2H); IR (Nujol)
oil. The oil was puri?ed by column chromatography
3530, 3450, 1735, 1720, 1612, 1592, 1550, 1515 cm—1.
(silica gel 30 g) using 4% ethyl acetate in CHZCIZ as an
EXAMPLE 67

20

p-Nitropheny N-(methyl
succinyl-L-alanyl-L-alanyl-L-prolymethyl)-N-methyl

yield. IR(CHC13): 0.9-1.5 (6H, m), 1.46 (9H, S), 1.8-2.2
(4H, m), 3.1-3.9 (4H, m), 3.9-5.0 (6H, m).

carbamate

This compound was prepared using the procedure of
Example 10: yield, 41%, mp l05°-l10° C., NMR
(CDCl3) & 1.1-1.5 (m, 6H), 1.8-2.2 (m, 4H), 2.4-2.8 (m,

4H), 3.0-3.4 (m, 3H),‘3.5-4.0 (m, 2H, 3.73 (s, 3H),
4.2-5.0 (m, 5H), 6.1-6.5 (m, 1H), 7.2-7.7 (m, 3H),
8.1-8.6 (m, 2H); IR (CHC13) 3300, 1735, 1640, 1520

eluting solvent to give 1.3 g of product as an oil 50.5%

25

EXAMPLE 73

N-(L-Prolylmethyl)-N-isopropyl-2-thioxo-3
thiazolidinecarboxamie Hydrochloride
HCl gas was passed through a solution of the com
30

cm-1. Anal. Calcd. for C25H33N5O10: C, 53.28; H, 5.90;
N, 12.43 Found: C, 53.53; H, 5.96; N, 12.36.

pound of Example 72 (1.10 g, 2.60 mmol) in ethyl ace
tate (30 ml) at r.t. for 5 min. The solution was allowed
to stand at r.t. for 20 min. The solution was evaporated

EXAMPLE 68

in vacuo to give an oil residue which was triturated

N-(N’-t-Boc-L-prolyl)methyl-N-t-butylamine

with ether to give a hydroscopic powder (0.70 g) of

This compound was prepared following the same
procedure as in Example 5: yield, 51%, NMR (CDC13)

1435 cm-l. NRM (&, DMSO-d6): 0.9-1.3 (6H, m),
1.8-21. (4H, m), 3.0-4.7 (12H, m).

product 883% yield, IR (CDC13): 3400, 1735, 1690,

& 1.12 (S, 9H), 1.47 (S, 9H), 1.8-2.2 (m, 4H), 3.5-3.8 (m,
2H), 3.74 (S, 2H), 4.4-4.6 (m, 1H), IR (Film) 3320, 1710,

EXAMPLE 74

1690 cm-l.
N-(Methyl

EXAMPLE 69

succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-isopro

p-Nitrophenyl N-(N’-t-Boc-L-prolyl

pyl-2-thioxo-3-thiazolidinecarboxamide

methyl)-N-t-butylcarbamate
This compound was prepared using the procedure of
Example 6: yellow oil, yield, 49%, NMR (CDC13) &
1.48 (S, 9H), 1.51 (s, 9H), 1.7-2.2 (m, 4H), 3.4-3.7 (m,

2H), 4.4-4.7 (m, 3H), 7.2-7.4 (m, 2H), 8.1-8.4 (m, 2H);
IR (Film) 1740, 1690 (br), 1615, 1593 c-l.

45

1.38 mmol) in acetonitrile (12 ml) at - 15° C. was added

50 —15° C. for 10 min. To the mixture at —15° C. was

added a suspension of the compound of Example 73 (0.5
g, 1.43 mmol) and N-methylmorpholine (0.18 ml, 1.64
mmol) in acetonitrile (14 ml). The mixture was stirred at

p-Nitrophenyl N-(L-prolymethyl)-N-t-butylcarbamate
hydrochloride
55

was separated, dried over anhydrous MgSO4, and evap
orated in vacuo to give an oil. The oil was puri?ed by
60

carbamate

1.8-2.3 (m 4H), 2.5-3.0 (m, 4H), 3.6-4.1 (m, 5H), 4.4-5.0

column chromatography (silica gel 30 g) using 2% ethyl
acetate in CH2C12 as an eluting solvent. The oil obtained
was triturated with ether to give a powder of the com

p-Nitrophenyl N-(Methyl
succinyl-L-alanyl-L-alanyl-L-prolylmethyl-N-t-butyl
This compound was prepared using the procedure of
Example 10: colorless crystals; yield, 16%; mp

- 15° C. for 45 min and then at r.t. for 2 hr. The precipi
tate was ?ltered off and the ?ltrate was diluted with

10% aqueous citric acid and CH2Cl1. The organic layer

4H), 2.8-3.5 (m, 2H), 4.0-4.9 (m, 3H), 6.9-7.5 (m, 2H),
8.0-8.4 (m, 2H).
EXAMPLE 71

To a solution of methyl succinyl-L-alanyl-L-alanine

(0.38 g, 1.38 mmol) and N-methylmorpholine (0.18 ml,
a solution of isobutyl chloroformate (0.23 ml, 1.38
mmol) in acetonitrile (5 ml). The mixture was stirred at

EXAMPLE 70

This compound was prepared using the procedure of
Example 8: brown powder; yield, 61%; mp 85°-90° C.
(dec); NMR (DMSO-d6) & 1.41 (S, 9H), 1.7-2.2 (m,

-

65

pound (0.35 g)., 44.3% yield. mp. IR (CHCl3): 3300,
1730, 1680, 1640, 1520, 1435 cm-1. NMR (&, CDC13):
0.9-1.6 (12H, m), 2.10 (4H, m), 2.63 (4H, m), 30-5.0
(12H, m), 3.73 (3H, S), 6.60 (1H, br d, J=7 Hz), 7.16
(1H, m).

21
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The organic layer was washed successively with 1120,

EXAMPLE 75

10% aqueous citric acid, H20, and saturated NaCl solu
tion, dried over anhydrous MgSO4, and evaporated in

' 2-Pyridyl N-(N'-t-Boc-L-prolyl)methyl-N-isopropyl

thiocarbamate
To a solution of N-(N'-t-Boc-L-prolyl)methyl-N-iso

vacuo to give an oil. The oil was puri?ed by silica gel

the compound of Example 89 (1.50 g, 8.64 mmol) IN

column chromatography (solvent, CHC13) to give a
0.51 g of the compound as an oil. 55.1% yield. IR
(Film): 1735, 1680, 1390, 1150 cm—l. NMR (&, CDC13):
1.27 (6H, d, J=7 Hz), 1.50 (9H, S), 1.8-2.2 (4H, m), 3.50

THF (30 ml) for 3 min. The solution was stirred at 5° C.
for 45 min and then at r.t. for 2 hr. The precipitate was

(2H, m).

propylamine (2.0 g, 7.4 mmol) and Et3N (1.2 ml, 8.6
mmol) in THF (12 ml) at 5° C. was added a solution of

(2H, 111), 4.0-4.7 (4H, m), 7.20-7.66 (2H, m), 7.80-8.20

?ltered off and the ?ltrate was evaporated in vacuo to

EXAMPLE 79

give an oil. The oil was puri?ed by silica gel column

Z-Benzothizolyl

chromatography (solvent, 5% ethyl acetate in CHzCl2)
to give 1.2 g of product as an oil 39.7% yield. IR (Film):

N-(L-prolylmethyl)-N—isopropylthiocarbamate

1735 (sh), 1690, 1615, 1570, 1560 cm-1, NMR (&,
CDCl3); 1.23 (6H, d, J =6 Hz), 1.53 (9H, S), 1.9-2.3 (4H,
m), 3.3—3.8 (2H, m), 4.1-5.0 (4H, m), 7.33 (1H, m), 7.80
(2H, m), 8.70 (1H, d, J=5 Hz).

pound of Example 78 (0.51 g, 1.1 mmol) in a mixture of
ethyl acetate (7 ml) and formic acid (1 ml) at 5° C. for 5

EXAMPLE 76

HCl gas was passed through a solution of the com

min. The solution was allowed to stand at r.t. for 10 min
20 and then evaporated in vacuo. To the oily residue was

added ethyl acetate and the ethyl acetate was evapo
rated in vacuo. This operation was repeated three times.
The residue obtained was triturated with ether to give a
powder which was collected and washed with ether to

2-pyridyl
N-(L-prolylmethyl)-N-isopropylthiocarbamate
Hydrochloride

HCl gas was passed through a solution of the com 25 give the compound (0.36 g), 82.3% yield. mp. 150°-156°

pound of Example 75 (1.1 g, 2.7 mmol) in ethyl acetate

C. IR (Nujol): 1745, 1655, 1545 cm-. NMR (&, DMSO

(40 ml) at r.t. for 5 min. The solution was allowed to
stand at r.t. for 20 min. Evaporation of the solvent gave

d6): 1.23 (6H, d, 7 Hz), 1.7-2.2(41-I, m), 3.0-3.6 (2H, m),
4.0-5.0 (41-1, m), 7.43-7.66 (21-1, in), 7.9-8.3 (2H, m).

a residue which was triturated with either to give a

Anal. calcd. for C17H21N302Sz.HCl.Q.5I-I20: C, 49.93;
H, 5.67; N, 10.27. Found: c, 49.94, H, 5.64; N, 10.40.

hygroscopic powder of product (0.7 g) 76.3% yield. IR
(CHC13): 1740, 1645, 1605, 1545 cm-1, NMR (&,
DMSO'd6)I 1.1-1.6 (6H, m), 1.8-2.2 (4H, m), 3.1-3.5
(2H, m), 4.0-5.0 (4H, m), 7.5-8.2 (3H, m), 8.7 (1H, in).

EXAMPLE 8O

2-Benzothiazoly1 N-(methyl
succinyl-L-alanyl—L-alanyl-L-prolylmethyl)-N-iso

EXAMPLE 77

2-Pyridy1 N-(Methyl
succinyl-L-alanyl—L-alanyl-L-prolylmethyl)-N-iso
propylthiocarbamate

35

To a solution of methyl succinyl-L-alanyl-L-alanine
(0140 g, 1.46 mmol) and N-methylmorpholine (0.16 ml,
1.46 mmol) in THF (12 m1) at —15° C. was added a

solution of isobutyl chloroformate (0.20 ml, 1.53 mmol)

propylthiocarbamate
To a solution of methyl succinyl-L-alanyl-L-alanine

(0.257 g, 0.936 mmol) and N-methylmorpholine (94.5
mg, 0.936 mmol) in acetonitrile (4 m1) at — 15° C. was

added a solution of isobutyl chloroformate (128 mg,
0.936 mmol) in acetonitrile (2 ml). The mixture was
stirred at — 15° C. and there was added a suspension of

in THF (15 mol) for 3 min. The mixture was stirred at
—15° C. for 10 min. To the mixture at —15° C. was

the compound of Example 79 (0.340 g, 0.851 mmol) and
N-methylmorpholine (103 mg, 1.02 mmol) in acetoni

stirred at - 15° C. for 0.5 hr and then at r.t. for 2.5 hr.

was washed successively with 10% aqueous citric acid,

added a suspension of the compound of Example 76. 45 trile (6 ml). The mixture was stirred at — 10° C. for 15
min and then at 5° C. for 1 hr 50 min. The reaction
(0.50 g, 1.46 mmol) and N-methylmorpholine (0.19 ml,
mixture
was diluted with CHZClZ. The organic layer
1.73 mmol) in acetonitrile (14 ml). The mixture was

The reaction mixture was diluted with CHgClz. The

organic layer was wahed with 10% aqueous citric acid,
dried over anhydrous MgSO4, and evaporated in vacuo

water, and saturated NaCl solution and dried over an

hydrous MgSO4. Evaporation of the solvent gave a
crude oil which was puri?ed by silica gel column chro

matography (solvent, 3% methanol in CH2C12) to give
a 0.47 g of crystalline residue. Recrystallization of the
a hygroscopic powder of desired compounds. (0.16 g).
crystals from tethyl acetate-hexane gave 0.35 g of de
mp. 19.5% yield. IR (CHC13): 3300, 1730, 1650, 1520
cm-1. NMR (&, CDC13): 1.1-1.6 (12H, m), 2.03 (4H, 55 sired compound. 66.4% yield. mp 169°-171° C. IR
(Nujol): 3350, 1730, 1690, 1655, 1530 cm-1. NMR (&,
m), 2.60 (4H, m), 3.5-40 (2H, m), 3.66 (3H, S), 4.1-5.2
CDC13): 1.0-1.6 (12H, m), 2.1 (4H, m), 2.63 (4H, m),
(6H, m), 6.76 (1H, d, J =8 Hz), 7.15-7.53 (2H, m), 7.66
3.5-4.0 (2H, rn), 3,70 (3H, S), 4.0-5.1 (6H, m), 7.03 (1H,
(2H, m), 8.60 (1H, brd, J =5 Hz).
brd, J =7 Hz), 7.3-8.2, (5H, m). Anal. Calcd. for
EXAMPLE 78
60 C23H37N5O7S2: C, 54.27; H, 6.02; N, 11.30. FOund=C,
2'-Benzothiazolyl
54.15; H, 6.03; N, 11.22.

to give an oil. The oil was triturated with ether to give

N-(N'-t-Boc-L-proly1)methyl-N—isopropylthiolcarba
mate

To a solution of the compound of Example 5 (0.54 g,

2.0 mmol) and Et3N (0.56 ml, 4.0 mmol) in THF (5 ml) 65
at 5° C. was added a solution of compound 90 (0.9 g, 3.8

EXAMPLE 81

l-Propyl-5-tetrazolyl
N-(N'-5—Boc—L-prolyl)methyl-N-isopropylthiocarba
mate

mmol) in THF (5 ml). The mixture was stirred at 5° C.

To a solution of a compound 5 (2.38 g, 8.8 mmol) and

for 2 hr. The reaction mixture was diluted with CHZCIZ.

Et3N (1.76 g, 0.0174 mol) in acetonitrile (10 m1) at 5° C.

23
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was added a solution of the compound of Example 91.

24

(3.0 g, 0.015 mol) in acetonitrile (8 ml) for 3 min. The

pound as an oil. 51% yield, IR (Film): 3200-3500, 1690,
1400 cm—l. NMR (&, CDC13): 1.43 (9H, 8), 1.7-2.1

mixture was stirred at 5° C. for 1 hr and then at r.t. for
2 hrs. The reaction mixture was evaorated in vacuo to

(4H, m), 2.30 (1H, brS), 3.3-3.8 (6H, m), 4.3 (11-1, m).
EXAMPLE 85

give a residue which was dissolved in CH2C12. The
CI-IgClg layer was washed with H20 and saturated NaCl

p-Nitrophenyl
N-(N’-5-Boc-L~prolyl)methyl-N-2-propynylcarbamate

solution, dried over anhydrous MgSO4, and evaporated
in vacuo. The oil was puri?ed by silica gel column

To a solution of the compound of Example 84 (1.0 g,

chromatography (solvent, 10% ethyl acetate in

3.76 mmol) and Et3N (0.65 ml, 4.7 mmol) in THF (12

CH2C12) to give 1.1 g of the compound as an oil. 29.8%

m1) at 5° C. was added a solution of p-nitrophenyl chlo

yield. IR (Film): 1735, 1680, 1390 cm—1. NMR (&,
CDC13): 1.00 (3H, t, J=7 Hz), 1.33 (6H, d, J=7 Hz),
1.50 (9H, S), 1.8-2.4 (6H, m), 3.53 (2H, m), 4.0-4.8 (4H,

roformate (0.75 g, 3.72 mmol) in THE (4 ml). The mix
ture was stirred at 5° C. for 1 hr and then at r.t. for 2 hr.
The reaction mixture was ?ltered and the ?ltrate was

m), 4.37 (2H, t, J =7 Hz.
EXAMPLE 82

15

l-Propyl-S-tetrazolyl
N-(L-proly1methy1)-N-isopropylthiocarbamate
Hydrochloride

evaporated in vacuo. The oil was purified by silica gel

column chromatography (solvent, CHC13) to give an oil
(1.60 g). 98.9% yield, IR (Film): 1730, 1680, 1610, 1590
cm—1. NMR (&, CDC13): 1.43 (9H, S), 2.0(41-1, m), 2.43

(1H, brS), 3.6-4.8 (71-1, m), 7.43 (2H, m), 8.33 (2H, brd,

J = 8 Hz).
HCl gas was passed through a solution of the com 20

pound of Example 81 (1.1 g, 2.6 mmol) in a mixture of
ethyl acetate (8 ml) and formic acid (6 ml) ar r.t. for 3

EXAMPLE 86

min. The solution was allowed to stand at r.t. for 10

N-(L4prolylmethyl)-N-2-propynylcarbamate

P-Nitrophenyl

min. The reaction mixture was evaporated in vacuo to
give an oil. To this oil was added ethyl acetate and the 25
ethyl acetate was evaporated in vacuo. The oil was

Hydrochloride
HCl gas was passed through a solution of the com

triturated with ether to give a'hygroscopic powder of

pound of Example 85. (1.40 g, 3.25 mmol) in ether (40

90 (0.4 g). NMR (&, DMSO-d6)=0.9-1.6 (9H, m),
1.7-2.3 (6H, m), 3.2-4.0 (2H, 111), 4.0-5.0 (6H, m).

ml) at r.t. for 5 min. The solution was allowed to stand
at r.t. for 15 min. The reaction mixture was evaporated
30 in vacuo to give a residue. Trituration of the oil with

EXAMPLE 83

ether gave a powder (0.36 g) of the compound. 30.1%
yield, mp 141°-152° C. IR (Nujol): 3300, 1740, 1720,

1-Propyl-5-tetrazolyl N-(methyl

succinyl-L-analyl-L-alany1-L-prolylmethyl)-N-iso
propylthiocarbamate
To a solution of methyl succinyl-L-Alanyl-L-alanine

35

1610, 1590, 1515 cm-1. NMR (&, DMSO-d6): 2.0 (4H,
m), 2.40 (1H, brS), 3.3-3.7 (2H, m), 4.0-4.8 (5H, m), 7.40
(2H, brd, J =8 Hz), 8.30 (2H, d, J =8 I-Iz).

(0.325 g, 1.31 mmol) and N-methylmorpholine (0.132 g,

EXAMPLE 87

1.31 mmol) in THF (3 ml) at -l5° C. was added a

-p-Nitrophenyl N-(methyl
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N
propynylcarbamate

solution of isobutyl chloroformate (0.179 g, 1.31 mmol)
in THF (1 ml). The mixture was stirred at — 15° C. for 40
10 min. To the mixture was added a suspension of the

To a solution of methyl succinyl-L-alanyl-L-alanine

compound of Example 83 (0.35 g, 0.93 mmol) and N
methylmorpholine (0.15 g, 1.5 mmol) in acetonitrile (4

(0.27 g, 0.99 mmol) and N-methylmorpholine (0.11 ml,

ml). The mixture was stirred at — 10° C. for 0.5 hr and
1.0 mmol) in THF (12 ml) at -15° C. was added a
then at 5° C. for 4 hrs. The reaction mixture was diluted 45 solution of isobutyl chloroformate (0.13 g, 0.95 mmol)

with CHgCl. The organic layer was washed succes
sively with 10% aqueous citric acid, water and satu
rated NaCl solution, dried over MgSO4, and evaporated
in vacuo. The oil obtained was puri?ed by silica gel

in THF. The mixture was stirred at — 15° C. for 15 min.

column chromatography (solvent, 3% methanol in

THF (14 ml). The mixture was stirred at — 15° C. for 1
hr. and then at r.t. for 2.5 hr. The reaction mixture was

To the mixture was added a mixture of the compound

86 (0.35 g, 0.95 mmol), N-methylmorpholine (0.11 ml,
1.0 mmol), and bis(trimethylsilyl)acetamide (1.5 ml) in

CHCl3) to give 0.13 g of the compound as an oil. The oil
was crystallized from ethyl acetate-hexane to give 39

diluted with CH2C12. The organic layer was washed
with 10% aqueous citric acid, dried over anhydrous
MgSO4, and evaporated in vacuo to give an oil. The oil

mg. 7.0% yield, mp 107°-108° C. IR (Nujol): 3350,

1735, 1685, 1655, 1530 cm-1. NMR (& CDC13): 1.00
(3H, t, J =7 Hz), 1.0-1.7 (12H, m), 1.7-2.3 (6h, m), 2.66
(4H, m), 3.5-4.0 (2H, m), 3.70 (3H S), 4.0-5.1 (8H, m),
6.83 (1H, d, 8 Hz), 7.50 (1H, m).

55

60

To a solution of (N-t-Boc-L-prolyl)chloromethane
(2.0 g, 8.1 mmol) in ether (50 ml) at 5° C. was added

2-propynylamine (2.2 ml, 0.032 mol). The solution was
stirred at 5° C. for 1.5 hr and then at r.t. for 1 hr. The

precipitate was ?ltered off and washed with ether. The 65
?ltrate was evaporated in vacuo to give an oil. The oil

was puri?ed by silica gel column chromatography (sol
vent, 3% methanol in CHC13) to give 1.1 g of the com

vent, 5% methanol in CHC13) to give an oil. Trituration

with ether gave a powder (0.21 g) of the compound.
37.7% yield. mp. 160°-163° C. IR (Nujol): 3340, 1740,

EXAMPLE 84

N-N’-t-Boc-L-pro1y1)methyI-N-Z-propynylamine

was puri?ed by silica gel column chromatography (sol

1690, 1655, 1635, 1595, 1520 cm-1. NMR (&, CDC13):
1.33 (6H, d, J =7 Hz), 2.03 (4H, m), 2.40(1I-1, brS), 2.60
(4H, m), 3.5-4.0 (2.H, m), 3.70 (3H, S), 4.1-5.0 (7H, m),
6.40 (1H, m), 7.10 (1H, d, J=7 Hz), 7.33 (2H, in), 8.30
(2H, d, J =9 Hz).
EXAMPLE 88

2-Thioxo 3-thiazolidinecarbonyl chloride
A solution of Z-mercaptothiazoline (2.0 g, 0.0168
mmol) and Et3N (2.9 ml, 0.021 mol) in THE (30 ml) was

25
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added dropwise to a solution of phosgene (2.37 g,
0.0239 mol) in toluene (12 ml) at 5° C. for 7 min. The

cm- 1. Anal. calcd for C24H26N4F3O6: C, 46.61; H, 4.24;
N, 9.06. Found C, 46.74, H, 4.27, N, 9.04.

mixture was stirred at 5° C. for 5 min and then ?ltered
to remove the precipitate. The ?ltrate was evaporated
in vacuo to give a crystalline residue. To the residue

EXAMPLE 94

Hepta?uorobutyl chloroformate
Triethylamine (3.66 ml, 26.3 mmol) was added drop

was added ether ( 10 ml) and the ether was evaporated in
vacuo. This operation was repeated twice. 2-Thioxo-3
thiazolidinecarbonyl chloride (2,0 g) was obtained as a

wise to a solution of hepta?uorobutanol (3.1 ml, 25

solid. 65.5% yield. IR (Nujol).

mmol) and phosgene (3.3 g, 30 mmol) in benzene (26 ml)
10 at 5° C. Themixture was stirred at 5° C. for 30 min and

EXAMPLE 89

at room temperature for 2 h, ?ltered and distilled. The
product distilled with benzene and was was used in the

Z-Pyridyl thiochloroformate

next step without further puri?cation. NMR (CDC13) &
4.70 (5, 2H, J=12.5 Hz; IR (Film) 1785 cm-1.

A solution of Z-mereaptopyridine (1.50 g, 0.0135 mol)
and Et3N (2.5 ml, 0.018 mol) in THF (24 ml) was added
dropwise to a solution of phosgene (1.53 g, 0.015 mol) in

EXAMPLE 95

toluene (8 ml) at 5° C. for 6 min. The mixture was
stirred at 5° C. for 5 min and then at r.t. for 5 min. The
reaction mixture was ?ltered and the ?ltrate was evapo

Penta?uorophenyl chloroformate
This compound was prepared according to the proce

rated in vacuo. To the residue was added ether and the

dure in Example 94: IR (Film) 1800, 1525 cm--‘.

ether was evaporated. This operation was repeated
twice. An oil of the compound (1.5 g) was obtained.

EXAMPLE 86

63.9% yield. IR (Film): 1765 c~1.

l-Phenyl-S-tetrazolyl chlorodithioformate

EXAMPLE 90
25

2-Benzothiazolyl thiochloroformate

To a solution of thiophosgene (1.29 g, 0.0112 mol) in
'THF (40 ml) at 5° C. was added a solution of l-phenyl

lH-tetrazole-S-thiol (2.0 g, 0.0112 mol) and Et3N (1.94

A solution of Z-mercaptobenzothiazole (0.669 g, 4.0
mmol) and Et3N (0.61 ml, 4.4 mmol) in THF (5 ml) was

ml, 0.0134 mol) in THF (30 ml). The mixture was stirred

added to a solution of phosgene (0.59 g, 6.0 mmol) in
at 5° C. for 30 min and then at r.t. for 1 hr. 20 min. The
toluene (3.1 ml) at 5° C. for 15 min. To the mixture was 30 precipitate was ?ltered and washed with THF. The
added acetonitrile (3 ml). The mixture was stirred at 5°
?ltrate was evaporated in vacuo. To the obtained resi
C. for 0.5 hr. The precipitate was ?ltered and washed
due was added ether and the insoluble material was
with THF. The ?ltrate was evaporated in vacuo to give
?ltered off. The ?ltrate was evaporated in vacuo to give
' a solid (0.9 g). IR (Nujol)=l775, 1605 cm*1.
a solid which was recrystallized from CHCl3--hexane.
35 0.91 g of the compound was obtained. 27.6% yield. 1R
EXAMPLE 91

(Nujol): 1725, 1585 cm-l.

l-Propyl-S-tetrazolyl thiochloroformate

EXAMPLE 97

A solution of S-mercapto-l-propyltetrazole (2.5 g,
0.0174 mol) and Et3N (2.65 ml, 0.0101 mol) in acetoni
trile (10 ml) was added to the solution of phosgene (2.58

l-Phenyl-S-tetrazolyl

N-(N’-5-Boc-L-proly1)methyl-N-isopropyldithiocarba

g, 0.0260 mol) in toluene (13.5 ml) at 5° C. for 50 min. '
The mixture was stirred at 5° C. for 50 min. The precipi
tate was ?ltered off and washed with THF. The ?ltrate
was evaporated in vacuo to give an oil (3.1 g). IR

mate

To a solution of compound 5 (1.30 g, 4.81 mmol) and
Et3N (0.83 ml, 5.7 mmol) in THF (14 ml) at 5° C. was
(Film): 1775, 1720 cm- 1. NMR (&, CDCl3)= 1.00 (3H, 45 added a solution of the compound of Example 96 (1.40
t, J =7 Hz), 2.10 (2H, m), 4.50 (2H, m).
g, 4.77 mmol in THF (14 ml) for 10 min. The solution
was stirred at 5° C. for 2 hr and then at r.t. for 2 hr. The

EXAMPLE 92

N-Tri?uoroacetyl-L-alanyl-L-alanine
This compound was prepared according to the

50

precipitate was ?ltered and washed with THF. The
?ltrate was evaporated in vacuo and the obtained oil

was puri?ed by silica gel column chromatography (sol

method by Schallenberg et al [E. E. Schallenberg and

vent, CHC13) to give 1.30 g of the compound as an oil.

M. Calvin, J. Amer. Chem. Soc. 77, 2779 (1955); J. L.
Dimicoli et a1. Biochemistry 15, 2230 (1976)]; yield based
‘on alanyl-a-alanine, 71.3%; mp 225°—235° C. (dec)

51.8% yield. IR (Film): 1740, 1690, 1595, 1395 cm—l.
NMR (&, CDC13): 1.0-1.6 (6H, m), 1.50 (9H, S), 1.8-2.3
(4H, m), 3.3-4.8 (6H, m), 7.63 (5H, S).

NMR (DMSO-d6 & 1.42 (d, J =7 Hz, 3H), 1.46 (d, J =7
Hz, 3H), 4.54 (1, J =7 Hz, 2H), 7.92 (d, J =8 Hz, 1H),
8.46 (d, J.=7 Hz, 1H); IR (Nujol) 3330, 3310, 3270, 1705,
1665, 1545 em-l.

EXAMPLE 98

/

EXAMPLE 93

Penta?uorophenyl
N-(tri?uoroacetyl-L-alanyl-L-alanyl-L-prolylmethyl)

60

l-Phenyl-S-tetrazolyl
N-(L-prolylmethyl)-N-isopropyldithiocarbamate
Hydrochloride
HCl gas was passed through a solution of compound
97 (1.20 g, 2.28 mmol) in ether (50 ml) at r.t. for 8 min.

N-isopropylcarbamate
The solution was allowed to stand at r.t.-for 15 min. The
This compound was prepared in a similar manner as 65 reaction mixture was evaporated in vacuo to give an oil

Example 10 colorless powder; yield 20.3%, mp 85°-88°
C., NMR (CDC13), & 0.9-1.9 (m, 12H), 1.9-2.5 (m, 4H),
3.3-5.0 (m, 8H), IR (Film) 3420 (b), 1715, 1670, 1555

of the compound (0.85 g), 87.4% yield. NMR (&,
DMSO-d6): 1.0-1.6 (6H, m), 1.8-2.3 (4H, m), 3.348

(6H. m), 7.73 (5H, s).

27
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EXAMPLE 99

l-Phenyl-S-tetrazolyl N-(methyl
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-iso
propyldithiocarbamate
To a solution of methyl succinyl-L-alanyl-L-alanine

(9.60 g, 2.20 mmol) and N-methylmorpholine (9.24 ml,
2.19 mmol) in THF (20 ml) at — 15° was added a solu

tion of isobutyl chloroformate (0.28 ml, 2.13 mmol) in
THF (5 ml). The mixture was stirred at — 15° C. for 15

-

e “

'

'28

luted with CI-ICl3. The organic layer was washed with
10% aqueous citric acid, dried over anhydrous MgSO4,
and evaporated in vacuo to give an oil. The oil was

crystallized from CHClg-hexane to give crystals of
compound 99. NMR (&, CDCl3); 0.9-1.6 (12H, m), 2.0
(4H, m), 2.53 (4H, m), 3.5-3.8 (2H, m), 3.63 (3H, s),
4.0-5.0 (6H, m), 7.0 (1H, m), 7.13-7.8 (5H, m).
The procedures described in Schemes I and II above
and the following Schemes III, IV, V and VI were

followed in preparing the compounds of the working

min. To the mixture was added a mixture of compound

examples described above. Set forth hereinafter are

98 (0.80 g, 1.86 mmol), N-methylmorpholine (0.24 ml,
2.19 mmol), and bis(trimethy1silyl)acetamide (2 ml) in

pared in the examples being indicated. The compounds

Schemes III, IV, V and VI with the compounds pre

of the intermediates and ?nal products are identified by
THF (14 ml). The mixture was stirred at - 15C for 0.5 hr
and then at r.t. for 2 hr. The reaction mixture was di 15 example numbers adjacent the de?nitions of R and R’.

4,643,991
-continued
Scheme Vl

HCLN

O

cmcnm
l

II

N \u/ s—<
s

active site is composed of an extended substrate binding
site that consists of a primary substrate binding site S],

N-N

MeOSuc-Ala—Ala
N

36

and aspartic acid that actually perform the peptide bond
hydrolysis. In addition to the catalytic residues, the
and various subsites on either side of the scissile bond.

The terminology of Schechter and Berger, Biochem.
Biophys. Res. Commun., 27, 157 1980) is used where

N

S2-S1-S1'-S2’ refer to subsites on both sides of the cata
lytic site of the enzyme and the notation P on the sub

strate (or inhibitor) denotes amino acid residues which
bind to these enzyme subsites, such that Pl-Pl’ repre
sents the bond which is cleaved. Substrate speci?city
studies with HL elastase, Powers et al, Biochem, Bio

99

cmcnm

I

MeO-Suc-Ala-Ala-N

N—N

phys, Acta., 485, p. 156, (1977), have shown that sub

N \H/ s—<
S

strates with the sequence MeOSuc-Ala-Ala-Pro-Val

(representing P5-P4-P3-P2-P1 are highly reactive with

N_N

the enzyme. The same sequence, although not idea]
with PP elastase, was found to react with it effectively.
In fact, HL elastase is similar to the more widely studied
20 PP elastase in many respects. They are both serine pro

99

teases that show esterase activity toward synthetic sub

As pointed out above, the compounds of the inven

strates such as Boc-Ala-ONp and are both inhibited by

tion are useful as elastase inhibitors. To evaluate the

cu-anti-trypsin. Furthermore, the natural substrates of

compounds, the inhibitory activity of the compounds

these enzymes are very similar.

were tested in vitro against the serine dependent proteo 25

The results of these evaluations are set forth in the

creatic elastase. All three enzymes belong to the family

following Tables 1, 2, and 3. The compounds tested as
shown in Tables 1, 2, 3, and 4 were prepared as de

of serine proteases where the catalytic residues are com

scribed above.

lytic enzymes, trypsin, chymotrypsin and porcine pan
posed of a triad of amino acid residues, serine, histidine

TABLE 1
Peptidyl Carbamates (ROCONR'R") where NR'R" is a Polypeptide
Effect of changes in P)’ on inhibitory activity towards PP elastase“)

Compound
No.
10

P1’

MeOSuc-Ala-A1a-Pro—CH2-N—CO—O

Ki
(FM)

Comments

mp” (°C.)

42.5

+

153-163

32.5

+

60-65

37.5

+

‘152-154

+

165466

—

125-127

+

84-87

N02

ll

MeOSuc-Ala-Ala-Pro-Clh-N-CO-O

58

F

F

MeOSuw-Ala-Ala-Pro-CI-b-N'-'CO'-'O

F
F

61

F

MeOSuc-Ala-Ala—Pro-—CH2—N—CO—O CHZCFZCFZCH

64

Me0Suc-Ala-—Ala—Pro-Clh-N-CO-SCH;

18

N __ N

III-N
CH3

14.8
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TABLE l-continued
Peptidyl Carbamates (ROCONR'R") where NR'R” is a Polypeptide
Effect of cha_nges in P1’ on ' Libitory activity towards PP ‘ ‘

‘U

Compound

Ki

No.

(HM)

Comments

mp” (°C.)

—

~50

('INONE OF THE LISTED COMPOUNDS EXHIBITED INHIBITION TOWARDS TRYPSIN AND CHYMOTRYPSIN
I

+ AT LEAST 70% INHIBITION OF PP ELASTASE OBSERVED IN 30 MIN AT -r[-El]—— = 260, [I] ~ 150 PM

— NO INHIBITION OF PP ELASTASE AT [I] < 150 ILM USING [E] = 0.61 MM
"ALL COMPOUNDS WERE NOVEL AND WERE IDENTIFIED BY SPECTRAL DATA AND ELEMENTAL ANALYSES‘

TABLE 2
Peptidyl Carbamates (ROCONR’R") where R'R"N is a Polypeptide:
Effect of changes in P] on inhibitory activity towards PP elastase.(')
Compound

_

Ki

No.
10

P1

(pM)

Comments

mp” (“C.)

42.5

+

153-163

30.5

+

161-166

+

155-160

+

105-110

—

147-151

MeOSuc-Ala-Ala—Pro-CH2—N—CO—O@ N02
29

MeOSue-AIa-AIa-Pro-CI-Ir-N—CO—O@ N02
32

Meosuc-Ala-A1a-Pro-cii2—N—co—0—@- N02
68

MeOSuc-Ala-Ala—Pro—CI-I2-I;I—CO—O—©>— N02
72

'

MeOSuc—A1a—Ala-Pro-CI-Ir-NN-CO-O

@

N02

(“NONE OF THE LISTED COMPOUNDS EXHIBITED INHIBITION TOWARDS TRYPSIN AND CHYMOTRYPSIN
I

+ AT LEAST 70% INHIBITIONOF PP ELASTASE OBSERVED IN 30 MIN ATL = 260, [I] ~ 150 ILM

[E]

- NO INHIBITION OF PP ELASTASE AT [I] < 150 ILM USING [E] = 0.61 pM
"ALL COMPOUNDS WERE NOVEL AND WERE IDENTIFIED BY SPECTRAL DATA AND ELEMENTAL ANALYSIS.

TABLE 3
Peptidyl Carbamates (ROCONR'R") where R'R"N is a polypeptide
Effect of Variations in P5 and P3 on inhibitory activity towards PP elastase
Compound

7

_

Ki

No.
58

I

P5

F

F

P3

MeOSue-AIw-Ala-Pro-CI-h-N-CO-O

F

(p‘M)

Comments

mp‘1 (°C.)

37.5

+

152-154

